Drug, bio-affecting and body treating compositions inventions 04/06

20060089297 - Sperm specific lysozyme-like proteins: The present invention is directed to a family of testis specific proteins (SLLPs) that share high sequence identity to lysozyme-C proteins. The application encompasses compositions comprising the SLLP proteins, antibodies specific for the SLLP polypeptides and the use of the SLLP polypeptides and antibodies directed to such peptides as contraceptive...

20060089300 - Macrocyclic peptides active against the hepatitis c virus: wherein R1 is (C1-8)alkyl, (C3-7)cycloalkyl, {(C1-6)alkyl-(C3-7)cycloalkyl} or Het, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1 is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6)alkyl, amido,...

20060089298 - Novel substances k01-b0171 and process for producing the same: The present invention is comprised of culturing a microorganism having ability to produce K01-B0171-B substance and/or K01-B0171-C substance in a medium, accumulating K01-B0171-B substance and/or K01-B0171-C substance in a culture fluid and isolating K01-B0171-B substance and/or, K01-B0171-C substance from the culture fluid. The obtained K01-B0171-B substance, K01-B0171-C substance or a...

20060089299 - Selective treatment of endothelial somatostatin receptors: The invention provides for the use of somatostatin receptor selective ligands (selective for SSTR1 or SSTR4) to treat human endothelial cells and to formulate medicaments for human use. The medicaments may for example be used to treat an angiogenic disease. In various embodiments, the angiogenic disease may for example be...

20060089301 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection: e

20060089303 - Cancer-testis antigens: Cancer-testis (CT) antigens have been identified by screening public databases for transcripts that are expressed in tumor tissues and a limited set of normal tissues, or by screening for genes that are expressed in cancer and testis tissues (but not other normal tissues). The invention relates to nucleic acids and...

20060089305 - Compositions and methods for activating toll-like receptor 4: Methods for activating Toll-like receptor 4 via cholesterol-dependent cytolysins isolated from a Gram-positive bacteria are provided. In addition compositions containing an isolated cholesterol-dependent cytolysin or a fragment thereof or a mimetic of the cytolysin or fragment thereof and methods for use of such composition in inhibiting binding and/or interaction of...

20060089302 - Hsp70-derived peptides and uses thereof in the diagnosis and treatment of autoimmune diseases: The invention relates to specific peptides derived from hsp70, and to pharmaceutical compositions comprising the same. The peptides and compositions of the invention are particularly suitable for the prevention or treatment of an autoimmune disease such as Type 1 Diabetes, Systemic Lupus Erithematosus, Multiple Sclerosis or Rheumatoid Arthritis. The invention...

20060089306 - New epilepsy mutations: An isolated nucleic acid molecule encoding a mutant alpha subunit of a mammalian voltage-gated sodium channel, wherein a mutation event selected from the group consisting of point mutations, deletions, insertions and rearrangements has occurred and said mutation event disrupts the functioning of an assembled sodium channel comprising this mutated subunit...

20060089304 - Treatment of psoriasis through down-regulation of the egf-receptor with topically-applied egf: From unrelated but similar fields it is deduced that certain forms of psoriasis can be effectively treated through topical application of EGF-containing formulations. This patent application summarizes the theoretical basis for this finding and requests protection for the idea, while clinical evaluation is in preparation....

20060089308 - Method of improving ovulation induction using an androgen such as dehydroepiandrosterone: A method of preconditioning ovulation induction in a human female comprises of administering an androgen, for example, DHEA, for at least about four consecutive months. DHEA may be administered along with high dose gonadotrophins in ovulation induction treatments. Moreover, DHEA may be administered with follicle stimulating hormone, human menopausal gonadotrophin,...

20060089307 - Peptides that bind to the heparin binding domian of vegf and vegfr-2: The present invention relates to new peptides for targeting that bind to the heparin binding domain of vascular endothelial growth factor and its receptor vascular endothelial growth factor receptor 2, VEGFR-2. The invention further relates to their use in therapeutically effective treatment as well as for diagnostic imaging techniques....

20060089309 - Stimulation of proliferation of pluripotential stem cells through administration of pregnancy associated compounds: The present invention provides for a method for stimulating the proliferation of pluripotential stem cells in a mammal comprising administration of pregnancy related compounds more particularly human chorionic gonadotropin, leutenizing hormone or prolactin. The present invention further provides for a method of treatment of tissues or organs experiencing cellular damage,...

20060089310 - Treatment of infections and other disorders: Microbial infections including anthrax infection, and gastrointestinal disorders, are treated or prevented by administration of an actin-sequestering peptide including amino acid sequence LKKTET, such as Thymosin β4, an isoform of Thymosin β4, oxidized Thymosin β4, or Tβ4 sulfoxide....

20060089311 - Agonists and antagonists of ryzn for the treatment of metabolic disorders: The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to,...

20060089313 - Methods and compositions for ameliorating the undesirable effects of chemotherapy: In one aspect, the present invention provides chemoprotectant compositions that each comprise at least two of the chemoprotectants disclosed herein. The chemoprotectant compositions of the invention are useful, for example, for ameliorating at least one adverse effect of chemotherapy. In another aspect, the present invention provides methods of ameliorating at...

20060089312 - Protease inhibitors: The present invention relates to prodrugs of protease inhibitors, such as inhibitors of proteosome, DPOP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease...

20060089314 - Image heating apparatus and method for manufacturing image heating apparatus: An image heating apparatus includes a heating roller for heating an image on a recording material; a coil unit disposed in said heating roller and including a coil for induction heat generation in said heating roller; a supporting member for rotatably supporting said heating roller, wherein said supporting member including...

20060089315 - Granular pesticidal composition:

20060089316 - Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof: Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels...

20060089317 - Treatment of metastatic breast cancer with anthracyclines, and taxanes: An improved adjuvant treatment of metastatic breast cancer in which patients are administered an anthracycline chemotherapeutic agent and a taxane chemotherapeutic agent is provided in which a diphenyl compound which is a potent antagonist of histamine binding at the intracellular histamine receptor is initially administered prior to administration of the...

20060089318 - Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases: The present invention provides compounds having the formula: (I); Also provided are pro-drug compounds of the formula: (II); The invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds. Methods for inhibiting an ADP-ribosyl transferase, ADP-ribosyl...

20060089319 - Method for treatment and prevention of bacterial vaginosis: Methods for treatment and prevention of bacterial vaginosis are described. In order to treat a patient diagnosed with bacterial vaginosis, an antibiotic is administered to the patient and all infected participant-partners. Bacterial vaginosis is prevented in a human patient planning to participate in activities in which the patient's vagina may...

20060089325 - Antisense modulation of ptp1b expression: Compositions and methods are provided for decreasing blood glucose levels in an animal or for preventing or delaying the onset of a rise in blood glucose levels in an animal, comprising administering to said animal an antisense inhibitor of PTP1B expression in combination with at least one glucose-lowering drug. The...

20060089322 - Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies: The present invention provides antisense oligonucleotides useful for identifying drug targets for cancer therapies and for enhancing current cancer therapies. The oligonucleotides of the invention are complementary to thymidylate synthase mRNA and affect expression of at least one other gene. For the enhancement of cancer therapies, such antisense oligonucleotides can...

20060089321 - Cks1 inhibitors: Inhibitors of human Cks1 and human Skp2, including antisense oligonucleotides, methods, and compositions specific for human Cks1 and human Skp2, are provided. Methods of using the compositions for modulating Cks1 expression and Skp2 expression, and for regulating cell growth, particularly tumor cell growth, are also provided....

20060089326 - Immunostimulatory nucleic acid molecules: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed....

20060089320 - Modulation of type iiß phosphoinositide phosphate kinase: The invention provides methods for modulating type IIβ phosphoinisitide phosphate kinase (PIPKIIβ) activity for treating PIPKIIβ-associated disorders. The invention also provides methods of identifying candidate agents for treating PIPKIIβ-associated disorders....

20060089323 - Rnai modulation of rsv, piv and other respiratory viruses and uses thereof: The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated...

20060089324 - Rnai modulation of rsv, piv and other respiratory viruses and uses thereof: The present invention is based on the in vivo demonstration that RSV and PIV can be inhibited through intranasal administration of RNAi agents as well as by parenteral administration of such agents. Further, it is shown that effective viral reduction can be achieved with more than one virus being treated...

20060089327 - Combinations comprising epothilones and anti-metabolites: Disclosed is a combination which comprises (a) an antineoplastic antimetabolite and (b) an epothilone derivative of formula (I), wherein A represents O or NRN, wherein RN is hydrogen or lower alkyl, R is hydrogen or lower alkyl, R′ is methyl, methoxy, ethoxy, amino, methylamino, dimethylamino, aminomethyl or methylthio, and Z...

20060089329 - Ready-to-use gemcitabine solution concentrates: Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solution concentrates....

20060089328 - Ready-to-use gemcitabine solutions: Provided are ready-to-use pharmaceutical compositions in the form of gemcitabine solutions....

20060089330 - Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans: One aspect of the present invention relates to solution-phase approaches to GPI synthesis. Another aspect of the present invention relates to key building blocks, and syntheses thereof, useful for GPI assembly. Yet another aspect of the invention relates to an automated method for the synthesis of GPIs and fragments thereof....

20060089331 - Methods and compositions for reducing toxicity of a pharmaceutical compound: The present disclosure is related to clear aqueous solutions of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. Solutions of the disclosure may be administered to a subject in conjunction with a pharmaceutical compound having one or more toxic effects. In...

20060089332 - Phosphate-bearing prodrugs of sulfonyl hydrazines as hypoxia-selective antineoplastic agents: e

20060089333 - Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents: wherein A+ represents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such...

20060089334 - Aminoalkylphosphonates and related compounds as edg receptor agonists: The present invention encompasses compounds or Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. Pharmaceutical compositions and methods of use are included....

20060089335 - Compositions and methods for enhancing cognitive function and synaptic plasticity: The present invention provides compositions and methods for enhancing cognitive function and synaptic plasticity. According to the method, Ca++ influx into excitatory neurons (nerve cells) is decreased by treatment with a number of different agents including divalent cations (e.g., Mg++), GABAB agonists, GABAA agonists, calcium channel blockers, and/or compounds that...

20060089336 - 4-dedimethylamino tetracycline compounds: The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux...

20060089338 - Dosage form for hormonal contraception: A dosage form for hormonal contraception containing a given number of hormone-containing daily units and a given number of hormone-free daily units for daily, oral administration, where the hormone-containing daily units each contain at most the minimum effective daily amount of folic acid for women and the hormone-free daily units...

20060089337 - Estrogen replacement regimen: The present invention provides an improved method to deliver estrogen to menopausal women comprising administering ultra-low dose estradiol alternating with standard-dose estradiol....

20060089339 - Method of improving cumulative embryo score and quantity of fertilized ooytes, increasing euploidy rate and of normalizing ovarian function using an androgen such as dehydroepiandrosterone: A method of improving cumulative embryo score may comprise administering an androgen to a human female, for example, DHEA, for at least about four consecutive months followed by harvesting and fertilizing oocytes and forming embryos. Between about 50 mg and about 100 mg of DHEA may be administered to a...

20060089340 - Novel steroids and steroid mimetics; method for their production; and use thereof: The invention relates to the production and use of novel 14β-alkyl-18-norsteroids, 8α,14β-dialkyl-18-norsteroids, spiro[cyclopentano-perhydronaphthalin]-3,1′-pentanes or hexanes in addition to 14β-fluoro-15β,17β-dihydroxy-steroids, by reacting 17-hydroxy-14,15-epoxi-steroids with water-free acids or Lewis acids and followed by derivatisation. The resulting compounds can be used as intermediate products for or as medicaments in human and veterinary medicine,...

20060089341 - Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands: The invention concerns low-molecular platinum complexes containing cyclobutane-1,1-dicarboxylate ligands that contain a protein-binding group....

20060089342 - Topical anti-microbial compositions: Disclosed are topical compositions for the treatment of microbial infections on the skin or scalp which include a polyvalent metal salt of pyrithione and include a metal ion source. Also disclosed are methods for treating microbial infections of the skin or scalp using such compositions....

20060089343 - Superoxide dismutase mimics for the treatment of ocular disorders and diseases: The use of SOD mimics, particularly Mn(III) porphyrin complexes, for the treatment of AMD, DR, and retinal edema is disclosed....

20060089344 - Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics: in which A=N or CR2; R2═H, F, OH, CN, CF3, C1-6-alkyl, C12-6-alkoxy; n=2 or 3 and m=2 when A=N; n=1, 2 or 3 and m=1 or 2 when A=CR2; B=covalent bond or C1-8-alkylene; R1=optionally substituted heteroaryl; R3═CHR4CONHR5; R4═H or C1-6-alkyl; R5═H, C1-6-alkyl, C3-7-cycloalkyl, C3-7-cycloalkyl-C1-C6-alkylene; in the form of a base,...

20060089345 - Indole derivatives, method for preparating same and pharmaceutical compositions containing same:

20060089346 - Novel lactams and uses thereof: Compounds having the formula (1) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid B protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to...

20060089347 - Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses: The present invention discloses novel substituted azepine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such azepines as well as methods of using them to...

20060089348 - Substituted quinoline-4-carboxylic hydrazides as nk-2/nk-3 receptor ligands: The present invention discloses a compound of formula (I): wherein: R1 is an aryl or heteroaryl ring; R2 is hydroxy, C1-6 alkoxy, C1-6 alkyl, amino, NR′R″ or C1-6 alkyl-NR′R″ where R′ and R″ are independently chosen from hydrogen and C1-4 alkyl and where R′ and R″, together with the nitrogen...

20060089349 - 11beta-hydroxysteroid dehydrogenase type 1 active compounds: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and are accordingly useful in the treatment...

20060089350 - Methods and compositions for the treatment of neuropsychiatric disorders: The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1....

20060089351 - Neuropeptide receptor modulators: e

20060089352 - Substituted thiazines as material protecting agents: The invention relates to novel thiazines of formula (I), wherein the substituents R1 to R7 have the designation cited in the description, and to the metallic salts and acid addition compounds thereof. Said novel thiazines have an excellent capacity for protecting technical materials from being infected by micro-organisms....

20060089353 - Indole derivative compounds and drugs containing the compounds as the active ingredient: (wherein the symbols in the formula are as mentioned in the specification) and a salt thereof Since the compounds represented by formula (I) binds to PGD2 receptors and shows antagonistic activity, they are believed to be useful for prevention and/or treatment of diseases such as allergic disease (such as allergic...

20060089354 - Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators: Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for...

20060089355 - Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides: Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting de-position of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R1, R2, R3, R4, R5, X1, and X2 are defined herein....

20060089356 - Substituted imidazoles as cannabinoid receptor modulators: The use of compounds of the present invention as antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor particularly in the treatment, prevention and suppression of diseases mediated by the Cannabinoid-1 (CB1) receptor. The invention is concerned with the use of these novel compounds to selectively antagonize the Cannabinoid-1 (CB1)...

20060089357 - Novel compounds and compositions as cathepsin inhibitors: The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making....

20060089358 - Pyrrolotriazine compounds: and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth...

20060089359 - Phthalazinone derivatives: d

20060089361 - Methods for treating retinal diseases: wherein the 2-imidazolin-2-ylamino group is in either the 5- or 6-position of the quinoxaline nucleus; x, y and z are in any of the remaining 5-, 6-, 7- or 8-positions and are selected from hydrogen, halogen, lower alkyl, lower alkoxy or trifluoromethyl; and R is an optional substituent in either...

20060089360 - Vanilloid receptor ligands and their use in treatments: Substituted nitrogen-containing heterocycles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with...

20060089362 - Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same: A compound represented by the formula (Ia) (wherein R1a, R2a, and R3 to R5 are the same as defined in the description), a prodrug thereof, a pharmaceutically acceptable salt thereof, or solvate thereof. The compounds are useful in the prevention of or treatment for diseases relating to NAD(P)H....

20060089363 - Antibacterial agents: Compounds of formula (II) have antibacterial activity: wherein Q represents a radical of formula —N(OH)CH(═0) or formula —C(═O)NH(OH); R1 represents hydrogen, methyl or trifluoromethyl, or, except when Z is a radical of formula —N(OH)CH(═0), a hydroxy, halo or amino group; R2 represents a group R10-(V)n-(ALK)m- wherein R10 represents hydrogen, or...

20060089364 - Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents: m

20060089365 - Heterocyclic compounds useful as nurr-1 activators: The present invention relates to compounds of formula (I): wherein R1 is hydroxy, C1-4 alkoxy, amino, C1-4 alkyl-amino, di C1-4alkylamino, benzyloxy or C2-C7 alkanoyl, R2 is C1-4 alkyl, C1-4 alkoxy, C1-4 alkoxy C1-4alkoxy, CF3, halogen, C1-4alkylamino, di C1-4alkylamino, di C1-4 alkylamino C1-4 alkoxy or N—C1-4 alkoxy C1-4 alkyl-N—C1-4 alkylamino, N—C1-4...

20060089366 - New piperazine and piperidine compounds: The invention relates to a group of novel piperazine and piperidine derivatives of the formula wherein Y is hydrogen, halogen, alkyl (1-3C), or CN, CF3, OCF3, SCF3, alkoxy(1-3C), amino or mono- or dialkyl(1-3C) substituted amino or hydroxy, X is O, S, SO or SO2, ---Z represents -C, =C or -N,...

20060089367 - New indole or benzimidazole derivatives as cb1 inverse agonists: and pharmaceutically acceptable salts thereof, processes for making said compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compound and pharmaceutically acceptable salts thereof, and methods of using said compounds. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1...

20060089368 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors: d

20060089369 - Inhibitors of glycogen synthase kinase 3: New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active...

20060089370 - Thieno-pyrimidine compounds having fungicidal activity: The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity....

20060089371 - Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist: in which the groups Q1-Q4, Ar, and R1-R7 are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment...

20060089372 - Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine: The invention concerns dihydroimi-dazo[5,1-a]-β-carboline compounds of general formula (1), wherein in particular, R1, R2, R2, Ra, R6 and K7, identical or different, independently of one another, represent a hydrogen, halogen atom, an alkyl, hydroxy, alkoxy, trihalogenoalkyl, alkylamino, dialkylamino, aryl, arylalkyl, carboxy, alkylcarbonyloxy, acyl, aryloxy or arylalkoxy group; R3 represents a...

20060089373 - High potency dopaminergic treatment of neurological impairment associated with brain injury: Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual who has sustained a brain injury comprising administering to the individual apomorphine. Methods and compositions are described for treating impaired neurological function, including altered state of consciousness disorders, in an individual...

20060089374 - Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease: Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications in patients with diabetes, metabolic syndrome, and/or hypertension. More particularly, aspects of the present invention are related to the use of cicletanine as a monotherapy or in...

20060089375 - Pyrazolo[3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors: and wherein X is NR4R5 or OR5a. The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic...

20060089376 - Tenatoprazole salts and process of preparation thereof: wherein X is Li, Na, Ca, K or Mg and to a process for the preparation thereof which comprises oxidizing a compound of formula (2) and isolating the salt (Li, Na) by treatment with the alkali hydroxide or exchanging the sodium salt of tenatoprazole with Mg++ or Ca++ cation....

20060089377 - Tenatoprazole salts and process of preparation thereof: wherein X is Li, Na, Ca, K or Mg and to a process for the preparation thereof which comprises oxidizing a compound of formula (2) and isolating the salt (Li, Na) by treatment with the alkali hydroxide or exchanging the sodium salt of tenatoprazole with Mg++ or Ca++ cation....

20060089378 - Tetrahydro-pyridinyl pyrazole cannabinoid modulators: e

20060089379 - Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity: The present invention is directed to compounds of the formula I: I(wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the...

20060089380 - 8-hydroxy quinoline derivatives: The present invention relates to a method for the treatment, amelioration and/or prophylaxis of a neurological condition, in particular neurodegenerative disorders which comprises the administration of an effective amount of a compound of formula (I): to a subject in need thereof. The present invention also relates to a compound of...

20060089381 - Method of producing ethyl (3r, 5s, 6e)-7-[2 cyclopropyl-4-(fluorophenyl) quinoline-3-yl]-3, 5-dihydroxy-6-heptenoate: A method of producing Ethyl (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinoline-3-yl]-3,5-dihydroxy-6-heptenoate by means of liquid chromatography using a packing material comprising a carrier and, carried thereon, a polysaccharide derivative, wherein a part or all of the hydrogen atoms of hydroxyl and amino groups of the polysaccharide derivative are substituted with one or more substituents, such...

20060089382 - Substituted 3-cyanoquinolines as mek inhibitors: The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an...

20060089383 - Substituted piperidine compounds and methods of their use: Novel 3,4-disubstituted-4-aryl-piperidine compounds are disclosed. Pharmaceutical compositions containing the 3,4-disubstituted-4-aryl-piperidine compounds and methods of their pharmaceutical uses are also disclosed. The compounds disclosed are useful, inter alia, as antagonists of opioid receptors....

20060089384 - Ophthalmic compositions and methods of using the same: Ophthalmic compositions are provided that comprise or consist essentially of (a) ketotifen or a ketotifen salt, (b) a non-ionic tonicity agent, and (c) water. The concentration of ketotifen or the ketotifen salt is preferably from 0.01% to 0.05%. The non-ionic tonicity agent is preferably glycerol and the concentration of the...

20060089385 - Pharmaceutical compositions: Forms and formulations of VX-950 and uses thereof....

20060089386 - Novel process for substituted sulfoxides: The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole....

20060089387 - Stabilized pharmaceutical composition comprising antidiabetic agent: This invention discloses a stabilized pharmaceutical composition comprising an antidiabetic agent and a stabilizer. The preferred stabilizers are selected from the group consisting of ascorbic acid, malic acid, maleic acid, tartaric acid, furmaric acid, citric acid, or combinations thereof. The antidiabetic agent is selected from the group consisting of [(±)5-[[2-(5-ethyl-2-pyridinyl)ethoxyl]phenyl]methyl]-thiazolidine-2,4-dione...

20060089388 - Use of parathyroid hormone-related protein (pthrp) in the diagnosis and treatment of chronic lung disease and other pathologies: This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung “health” and “disease, and can be used to predict lung disease in patients at...

20060089389 - Combination: (i) an AT1-receptor antagonist or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier....

20060089390 - 3-benzoyl-2,4,5-substituted pyridine derivatives or salts thereof and bactericides containing the same: To provide 3-benzoyl-2,4,5-substituted pyridine derivatives or their salts, fungicides containing them, and intermediates for producing them. By providing a group of compounds comprising specific 3-benzoyl-2,4,5-substituted pyridine derivatives or their salts, or fungicides containing them, which have so-called rainfastness, whereby they are capable of exhibiting excellent effects even when crops have...

20060089391 - Treatment of cancer in pediatric patients: Compositions comprising a cancer drug, a continuous oral dosing schedule with a drug which binds to the colchicine site of tubulin β-subunits, and methods of treating cancer in a pediatric patient using continuous dosing schedules are disclosed....

20060089392 - Ester derivatives and medicinal use thereof: or its pharmaceutically acceptable salt, or use of the same. The compound represented by the formula [1] or its pharmaceutically acceptable salt is useful as an agent for the treatment or prophylaxis of hyperlipidemia or the like, since it disappears very rapidly in the living body and has an excellent...

20060089393 - Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors: Compounds of formula (I) are inhibitors of p38 kinase and are useful in the treatment of conditions or disease states mediated by p38 kinase activity or mediated by cytokines produced by the activity of p38....

20060089394 - Phenylalkanoic acid and phenyloxyalkanoic acid derivatives as hppar activators: A compound of formula (I) or a pharmaceutically acceptable salt, solvate, or hydrolysable ester thereof, wherein:...

20060089395 - Nf-kb activation inhibitors: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is {circle around (1)} a fused polycyclic heteroaryl group wherein the ring...

20060089396 - Halogenated benzamide derivatives: e

20060089397 - Synthetic diazonamides: The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate Diazona angulata useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds....

20060089398 - Isoxazole carboxamide derivatives as ghrelin receptor modulators: or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by ghrelin including anorexia, cancer cachexia, eating disorders, age-related decline in body composition, weight gain, obesity, and diabetes mellitus....

20060089399 - Pyrazolyl carboxanilides for controlling unwanted microorganisms:

20060089400 - Novel spiro ketone and carboxylic acid derivatives as specific inhibitors for (po3h2) ser/(po3h2)thr-pro-specific peptidyl-prolylcis/trans-isomerases: The invention provides new spiro and carboxylic acid derivatives, pharmaceutically compositions comprising them and their use for the preparation of pharmaceutical compositions....

20060089401 - Kinase inhibitors: The present invention provides a method for identifying inhibitors of protein kinases. Methods are also provided for inhibiting protein kinase activity. Specific non-peptide protein tyrosine kinase inhibitors are provided. The protein kinases produced using the method of the present invention may be used to treat a number of conditions in...

20060089402 - Compounds from antrodia camphorata and use thereof: The present invention relates to novel compounds from Antrodia camphorata and the use thereof....

20060089403 - Mono-acylated o-phenylendiamines derivatives: e

20060089404 - Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders: A class of chromane and chromene compounds having the structure shown below and pharmaceutically acceptable salts thereof are useful as therapeutic compounds, particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae...

20060089405 - Asymmetric synthesis of dihydrobenzofuran derivatives: c

20060089406 - Inhibitors of the fatty acid oxidation for the prophylaxis and/or the treatment of chronic and/or atopic skin diseases: The invention relates to a method of preventing and/or treating a chronic and/or an atopic skin disease by administering an inhibitor of fatty acid oxidation to a patient in a pharmacologically effective amount. Furthermore, the invention relates to the use of at least one inhibitor of fatty acid oxidation for...

20060089407 - Methods for making and using synergistic multifunctional compositions: The present invention is a synergistic palliative and/or therapeutic admixture for treating and/or medicating affected biological tissue in mammals. The admixture includes two or more multivalent metals and at least one polyfunctional organic ligand. The ligand is in the form of an alkaline earth salt. The molar ratio of metal...

20060089408 - Method of treating blepharospasm with a prostaglandin derivative: The present invention is a method of treating blepharospasm with a prostaglandin derivative, comprising the steps of (a) providing a predetermined amount of prostaglandin derivative; and (b) applying the prostaglandin derivative in a predetermined position. The prostaglandin derivative is preferably in the form of latanoprost wherein the chemical composition of...

20060089409 - Novel analogs of 3-o-acetyl-11-keto-ß-boswellic acid: These compounds exhibited 5-Lipoxigenase inhibitory properties and these compounds may be used in pharmaceutical compositions for therapeutic applications against a variety of inflammations and hypersensitivity-based human diseases including asthma, arthritis, bowel diseases such as ulcerative colitis and circulatory disorders such as shock and ischaemia. These compounds also inhibited the growth...

20060089410 - Combination of chemotherapeutic drugs for increasing antitumor activity: An oxyalkylene group containing histone deacetylase(s) inhibitor is used sequentially with another antineoplastic agent to increase antitumor activity in cells and mammals....

20060089411 - Treatment of stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin: Zeaxanthin, a natural carotenoid, can improve and increase the ability of enzyme inhibitors that can slow down certain enzymes that are contributing to toxic metabolite accumulation in people who suffer from Stargardt's disease or other lipofuscin disorders. Such enzyme inhibitors include retinoid analogs such as isotretinoin, commonly known by the...

20060089412 - Pharmaceutical composition for the treatment of non-alcoholic fatty liver disease: There is provided a method of preventing or treating non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis, which comprises administering a pharmaceutical composition comprising L-alanine as an active ingredient to a patient suffering from the disease. This pharmaceutical composition is safe and efficacious for prevention and/or therapeutic treatment of non-alcoholic fatty...

20060089413 - Anthranilic acid amides and derivatives thereof as cosmetic and pharmaceutical agents: e

20060089414 - Generic probes for the detection of phosphorylated sequences: Generic probes that bind to phosphorylated amino acid residues are provided as well as methods employing the probes for screening for kinase inhibitory activity, kinase activity, and phosphatase activity. Methods for distinguishing serine/threonine kinase phosphorylation from tyrosine kinase phosphorylation are also provided....

20060089415 - Anti-infective agents and methods of use: n

20060084590 - Methods of and compounds for modulating the activity of bacterial fabg: Prokaryotic FAB G polypeptides and DNA (RNA) encoding such FAB G and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such FAB G for the treatment of infection, such as bacterial infections. Antagonists against such FAB G and their use as...

20060084592 - Peptide boronic acid inhibitors: o

20060084591 - Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases: The present invention describes the use of modulators of the signal transduction pathway via the protein kinase Fyn (e.g. Rho-kinase inhibitors or inhibitors of the protein kinase CSK) in the treatment of tumour diseases, especially in the therapy of neuroblastoma....

20060084593 - Anti-hiv composition, production method thereof and medicament: The present invention relates to an anti-HIV composition and to the method for producing it. The composition of the present invention comprises a polyanion and a molecule capable of inducing the exposure of the CD4i epitope of the gp120 viral protein. The polyanion may be chosen, for example, from the...

20060084595 - Complex comprising ocif and polysaccharide: A complex comprising at least one substance selected from the group consisting of an osteoclastogenesis inhibitory factor, an analogue thereof and a variant thereof, which is bound to at least one substance selected from the group consisting of a polysaccharide and a polysaccharide derivative. The complex has a prolonged retention...

20060084594 - Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer: The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also...

20060084596 - Growth factor binding molecules: Growth factor binding molecules having a plurality of peptide loops attached to a non-peptide organic scaffold, preferably having pseudo-six amino acid peptide loops with four amino acid sidechains. The growth factor binding molecules specifically bind various growth factors and are suitable for treating a subject having tumors or restinosis. In...

20060084599 - Compositions, methods and kits relating to notch signaling: The present invention relates to methods and compositions based on the modulation of Src-mediated cortactin phosphorylation. In particular, the invention features methods and compositions for modulating Src-mediated cortactin phosphorylation using Notch ligands to modulate Notch signaling....

20060084600 - Human homologues of fused gene: The invention relates to novel molecules, in particular nucleic acid sequences and the encoded polypeptides, which are the human homologues of the protein-serine/threonine kinase named Fused....

20060084603 - Igf-bp3-related methods for inhibiting tumor growth: The subject invention provides a method of inhibiting the proliferation of cells associated with a tumor in a subject which comprises administering to the subject between about 10 μg/kg and about 100 mg/kg of IGF-BP3, thereby inhibiting proliferation of the cells. The subject invention further provides a surgical method which...

20060084601 - Method for treating respiratory distress syndrome: The invention provides a method for treating infants, children or adults suffering from pulmonary distress caused by low or insufficient production of surfactant. It is particularly suitable for treating premature infants suffering from Respiratory Distress Syndrome. The method comprises administering a leptin compound to an individual with impaired surfactant production...

20060084602 - Platelet-derived growth factor compositions and methods of use thereof: A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/mL to about 1.0 mg/mL in a pharmaceutically acceptable liquid carrier and...

20060084605 - Stable pharmaceutical compositions: Pharmaceutical composition for parenteral administration comprising a glucagon-like peptide and human serum albumin or a variant thereof....

20060084604 - Transepithelial delivery of peptides with incretin hormone activities: Compositions and methods are disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially using a transepithelial carrier peptide....

20060084598 - Use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia: The invention is based on the use of alpha-1 antitrypsin for the preparation of medicaments for the treatment of fibromyalgia, comprising the preparation of therapeutic concentrates of alpha-1 antitrypsin, in any form of administration tolerated by humans, the alpha-1 antitrypsin being obtained by purification of human plasma or being produced...

20060084597 - Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity: Use of a compound having 50% activity or more of the activity of gastric inhibitory polypeptide, GIP, when tested in the same assay under the same conditions, and/or the use of GIP, analogues and fragments thereof, for the manufacture of a pharmaceutical composition for prophylaxis and/or treatment of conditions caused...

20060084606 - Methods for reducing oxidative damage: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three...

20060084607 - Purified amphiphilic peptide compositions and uses thereof: A plurality of amphiphilic peptide chains having alternating hydrophilic and hydrophobic amino acids, wherein the peptide contains at least 8 amino acids, are complementary and structurally compatible, and self-assemble into a beta-sheet macroscopic scaffold wherein peptide at least about 75% of the chains have the same sequence....

20060084608 - Binding polypeptides and methods based thereon: Binding polypeptides that specifically bind BLyS protein or BLyS-like polypeptides can be used in methods of the invention for detecting, diagnosing, or prognosing a disease or disorder associated with aberrant BLyS or BLyS receptor expression or inappropriate function of BLyS or BLyS receptor, comprising BLyS binding polypeptides or fragments or...

20060084609 - Synthetic hla binding wt-1 peptide analogues and uses thereof: The present invention is directed to a synthetic peptide comprising a sequence of amino acids containing at least a segment that is an analogue of a native peptide that specifically binds to HLA A0201 or HLA A0301 molecules on a cell characteristic of a pathophysiologic state in a mammal. The...

20060084611 - Apoptotic compounds: The invention provides methods and compositions for enhancing apoptosis of pathogenic cells. The general method comprises the of contacting the cells with an effective amount of an AV peptoid, wherein the AV peptoid is a peptide comprising AX1, wherein X1 is V, I or L, or a peptide mimetic thereof,...

20060084610 - Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments: This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by...

20060084612 - Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors: The present invention provides the combined use of acryloyl distamycin derivatives, in particular α-bromo- and α-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and a protein kinase (serine/threonine and tyrosine kinases) inhibitor, in the treatment of tumors. Also provided is the use of the said combinations...

20060084613 - Inhibitors of the ice/ced-3 family of cysteine proteases: wherein A, B, R, R1, R1′ p and q are as defined herein. The invention is also directed to pharmaceutical compositions containing one or more of these compounds, as well as to the use of such compositions in the treatment of patients suffering inflammatory, autoimmune and neurodegenerative diseases, for the...

20060084614 - Novel factor viia inhibiting compounds: e

20060084615 - Puerarin derivatives and their medical uses: The present invention provides acetylated derivatives of the compound puerarin that have enhanced bioavailability and are particularly suitable for oral administration. The present invention also teaches the use of medicaments containing acetylated derivatives of puerarin that are suitable for the treatment of myocardial ischemia and for modulating blood lipid levels,...

20060084616 - Inhibitors of adp-ribosyl transferases, cyclases, and hydrolases, and uses thereof: wherein A is chosen from a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group; both B and C are hydrogen, or either B or C is a halogen, amino, or thiol group and the other of B or C is hydrogen; and D is a primary alcohol, a...

20060084618 - Adiponectin promoter and use thereof: The present invention relates to a DNA having a promoter region containing regulatory sequences of human adiponectin gene, transformants transformed with the DNA, a screening method of a compound which can enhance the human adiponectin promoter activity, which the transformants are used, and the screening kit, and a screening method...

20060084622 - Angiogenic factor and use thereof in treating cardiovascular disease: The present invention relates to a novel VEGF protein product, and nucleic acid encoding the novel protein product, comprising exons 1-6 and 8 of the VEGF gene, and its use thereof in treating the cardiovascular system and its diseases through effects on anatomy, conduit function, and permeability. VEGF145 has been...

20060084621 - Compositions and methods for inhibiting expression of anti-apoptotic genes: The present invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of an anti-apoptotic gene, comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of an apoptotic gene, such as...

20060084623 - Dna vaccination for treatment of multiple sclerosis and insulin-dependent diabetes mellitus: A pro-inflammatory T cell response is specifically suppressed by the injection into a recipient of DNA encoding an autoantigen associated with autoimmune disease. The recipient may be further treating by co-vaccination with a DNA encoding a Th2 cytokine, particularly encoding IL4. In response to the vaccination, the proliferation of autoantigen-reactive...

20060084617 - Methods for delivery of nucleic acids: This invention features methods and compositions for delivery of nucleic acids (e.g., DNA, RNA, PNA, and hybrids thereof) to cells. The nucleic acid delivery complexes of the invention permit biologically active nucleic acids to be delivered to cells and organisms in vitro and in vivo in a manner and form...

20060084619 - Novel neurotrophic factor protein and uses thereof: The present invention discloses a novel neurotrophic factor protein, MANF2 and a genetic sequence encoding the same. The molecule will be useful in the development of a range of therapeutics and diagnostics useful in the treatment, prophylaxis and/or diagnosis of MANF2 dependent conditions. The molecule of the present invention is...

20060084620 - Rna interference in respiratory epitheial cells: The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules....

20060084624 - Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis b: wherein R is selected from the group consisting of H, straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate derivative; and BASE is a purine or pyrimidine base which may be optionally substituted. The...

20060084626 - Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist: Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenias; and inhibition of abnormal cell...

20060084625 - Use of a2a adenosine receptor agonists: Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A2A receptor agonist—to a human undergoing myocardial imaging in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity....

20060084628 - Combination therapy for treating viral infections: A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) infections, by administering Elvucitabine and a second active agent to a patient suffering viral infection is provided herein. The second active agent is, for example, an immunomodulatory compound, an anti-viral agent, or a combination comprising...

20060084627 - Synergistic interaction of abacavir and alovudine: A pharmaceutical preparation comprising a synergistic combination of abacavir and alovudine and a pharmaceutical carrier therefor. Use of abacavir and alovudine together for the treatment of multiresistant HIV, wherein the use comprises simultaneous, combined or sequential administration of alovudine and abacavir....

20060084631 - Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof: Methods and compositions for treating or preventing microbial infection in mammals with sulfated polysaccharides wherein the polysaccharides have a degree of sulfation effective to enable maximal interaction of constituent sulfate groups with the microbe which causes the infection and wherein the sulfated polysaccharide is not substantially endocytosed or degraded by...

20060084629 - Immune system activating formula composed of selected long chain polysaccharides from natural sources: A combination of two, specialized, high molecular weight-long chain fractions isolated from Aloe Vera and Maitake TD to stimulate immune system activity comprise long chain-high molecular weight polysaccharides which activate the body's natural immune response, triggering an increase in the production of macrophages, T-cells, B-cells, natural killer cells, cytokines and...

20060084630 - Method for synthesis of beta glucans: The invention provides a method for forming P-glucoside linkages in carbohydrate polymers, particularly synthetic glucan molecules, by attaching a protecting group to the C2 position of a glucoside donor. The protecting group of the invention stabilizes the dioxolenium ion and prevents orthoester formation to promote the β linkage and inhibit...

20060084632 - Topical gel formulation comprising organophosphate insecticide and its preparation thereof: The present invention provides a topical gel pharmaceutical formulation of insecticide suitable for treating an ectoparasite in a mammal, comprising: a) about 0.1-10% by weight of an insecticide; b) at least about 75% by weight of an organic solvent selected from the group consisting of a lower alkyl alcohol, a...

20060084634 - 7-pyrollyl tetracycline compounds and methods of use thereof: A compound of Formula (I):...

20060084633 - Formulations for treating or preventing mucositis: Mucositis is treated and/or prevented by administrating to a patient a formulation comprising a tetracycline that is poorly absorbed from the gastro-intestinal tract. The tetracycline may be in the form of a pharmaceutically acceptable salt or a base. The formulations may optionally also contain an antifungal agent to prevent fungal...

20060084635 - Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease: A medicament for the amelioration and treatment of vascular disease consisting of aspirin administered in combination with one or more of the vitamins including vitamin A, vitamin B6, vitamin C, vitamin E, and niacin. Alternative embodiments include the administration of aspirin in combination with one or more trace element including...

20060084636 - Methods of using fatty-acid esters of estrogens and serotonin reuptake inhibiting compounds for reducing the body weight of a mammal and compositions containing the same: Compositions and methods for reducing the body weight of a mammal are disclosed. The invention is directed to methods for reducing the body weight in a mammal comprising administering therapeutically effective amounts of a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a serotonin reuptake-inhibiting compound....

20060084638 - Appetite-suppressing compositions and methods: The invention relates to appetite-suppressing compositions obtained from botanical sources. More specifically, the invention relates to appetite-suppressing compositions comprising an extract product of an Asclepias plant, methods of making an appetite-suppressing composition, and methods of suppressing an appetite....

20060084637 - Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same: Compositions and methods for reducing the body weight of a mammal are disclosed. The invention is directed to methods for reducing the body weight in a mammal comprising administering therapeutically effective amounts of a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a thermogenic compound. Furthermore...

20060084639 - Compositions containing piperacillin and tazobactam useful for injection: The invention provides a pharmaceutical composition comprising piperacillin, tazobactam, an aminocarboxylic acid, and a buffer in a sodium lactate diluent. The invention further relates to a method of treating a bacterial infection and an LR condition in a human which comprises administering to said human an effective amount of a...

20060084641 - Il-8 receptor antagonists: This invention relates to the novel use of sulfonamide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8)....

20060084640 - Vanilloid receptor ligands and their use in treatments: Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory...

20060084642 - Substituted imidazol[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives: R3 is hydrogen, methyl or aryl; R is lower alkyl, cycloalkyl or aryl; and pharmaceutically acceptable acid addition salts thereof. Such compounds have a high affinity and selectivity for GABA A α5 receptor binding sites and might be useful as cognitive enhancer or for the treatment of cognitive disorders, anxiety,...

20060084643 - Piperazine substituted aryl benzodiazepines:

20060084644 - Novel pyridine compounds, process for their preparation and compositions containing them: The present invention provides new heterocyclic compounds, particularly substituted pyridines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan....

20060084645 - Novel pyrimidine compounds, process for their preparation and compositions containing them: The present invention provides new heterocyclic compounds, particularly substituted pyrimidines, methods and compositions for making and using these heterocyclic compounds, and methods for treating a variety of diseases and disease states, including atherosclerosis, arthritis, restenosis, diabetic nephropathy, or dyslipidemia, or disease states mediated by the low expression of Perlecan....

20060084646 - Method of preparing alkylated salicylamides via a dicarboxylate intermediate: The present invention relates to a method of preparing an alkylated salicylamide from a protected and activated salicylamide via a dicarboxylated salicylamide intermediate. The present invention also relates to dicarboxylic salicylamide delivery agent compounds for the delivery of active agents. Methods of administration are provided as well....

20060084647 - Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof: The invention relates to small molecules which function as inhibitors of anti-apoptotic Bcl-2 family member proteins (e.g., Bcl-2 and Bcl-xL). The invention also relates to the use of these compounds for inducing apoptotic cell death and sensitizing cells to the induction of apoptotic cell death....

20060084648 - Ethynyl derivatives as factor xa inhibitors: Novel compounds of the formula (I), in which R1, R2, R3, X and Y have the meaning indicated in Patent claim 1, are inhibitors ocoagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours....

20060084649 - Substituted alkyl amido piperidines: This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective...

20060084650 - Kinase inhibitors: i

20060084652 - Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents:

20060084653 - Beta-sheet mimetics and composition and methods relating thereto: including pharmaceutically acceptable salts and stereoisomers thereof, wherein A, A′, B, X, Y, R2, R3, R4 and R5 are as defined herein. Such compounds have utility over a wide range of applications, including use as diagnostic and therapeutic agents. In particular, compounds of this invention, and pharmaceutical compositions containing such...

20060084651 - Chemical compounds: The present invention relates to aminopyrazine derivatives, compositions and medicaments containing the same, as well as processes for the preparation and use of such compounds, compositions and medcicaments. Such aminopyrazine derivatives are useful in the treatment of diseases associated with inappropriate tyrosine and/or serine/threonine kinase activity....

20060084656 - Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline: A composition for nasal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient. The invention also provides a composition for buccal administration comprising varenicline or its pharmaceutically acceptable salt and at least one excipient to form a solid dosage form, wherein the solid dosage form disintegrates...

20060084654 - Imidazopyrazine tyrosine kinase inhibitors: c

20060084655 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed...

20060084657 - Piperazine derivative: wherein n is an integer of 1 to 8; R1 represents hydrogen or C1-10 alkyl; A represents CH or nitrogen; Ar1 represents phenyl or substituted phenyl; and Y represents a group represented by the formula Y1-Y2-Ar2 or Y3-Y4(Ar5)-Ar6 or a pharmaceutically acceptable salt of the derivative. The novel piperazine derivative...

20060084658 - Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound: In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group...

20060084659 - Augmentation of psychotherapy with cannabinoid reuptake inhibitors: Methods are provided for facilitating psychological extinction of a deleterious, high-anxiety response that is disproportionate to the threat offered by a given stimulus. An afflicted subject is treated with a cannabinoid reuptake inhibitor in conjunction with extinction training. The methods are relevant for treatment of anxiety disorders, including phobic disorders...

20060084660 - Calcium channel blockers comprising two benzhydril moieties: Certain piperazine compounds are described which are useful in altering calcium channel activity....

20060084661 - Il-8 receptor antagonists: This invention relates to the novel use of amide squaramides in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8)....

20060084662 - Phenyl-piperazine derivatives as serotonin reuptake inhibitors: i

20060084663 - Peroxisome proliferator activated receptor modulators: The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts thereof, Formula I: wherein: (a) R5 is selected from the group consisting of (C1-C6) alkyl, (C1-C6) alkenyl, substituted aryl(C0-C4)alkyl, substituted aryloxy(C0-C4)alkyl, substituted arylthio(C0-C4)alkyl, unsubstituted aryl(C0-C4)alkyl, unsubstituted aryloxy(C0-C4)alkyl, and unsubstituted arylthio(C0-C4)alkyl; (b) T1 is...

20060084665 - Quinolizinone compound and use thereof as hiv integrase inhibitor: wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and an anti-HIV agent containing same as an active ingredient. The compound of the present invention has an HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS....

20060084664 - Substituted pyrido(1,2-a) pyrimidines and their use as nos inhibitors: e

20060084666 - Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient a therapeutically effective amount of an EGFR kinase inhibitor, combined with treating the patient simultaneously or sequentially with radiation therapy, with or without additional agents or treatments, such as other...

20060084667 - New derivatives of amidines, their preparation, their use as medicaments and the pharmaceutical compositions containing them: e

20060084668 - Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard: The present invention provides an isolated N-formyl valacyclovir, its preaparation and its use as a reference marker and/or reference standard....

20060084669 - Processes for the production of chinazoline alkaloids: e

20060084670 - Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer: The present invention relates to therapeutic associations for the treatment of cancer, comprising an effective amount of a camptothecin, or a camptothecin derivative, with an effective amount of an alkylating agent such as a platin derivative, and methods of using such therapeutic associations....

20060084671 - Process for the preparation of pure finasteride: e

20060084672 - Method for modification of y-secretase activity through inhibition of fkbp13: The present invention provides a method for modifying γ-secretase activity in a cell or in an organism by de-stabilizing presenilin through inhibition of Fkbp13. Inhibition of Fkbp13 de-stabilizes presenilin and prevents formation of a functional γ-secretase complex thus decreasing γ-secretase activity and concomitantly decreasing production of amyloid-β peptides. The invention...

20060084673 - 1,5-naphthyridine azolinone: 1,5-Naphthyridine azolinone derivatives are disclosed. These compounds are inhibitors of CDK1 and are useful as antiproliferative agents, such as anti-cancer agents....

20060084674 - Azaindole thiazolinones: Azaindole thiazolinone derivatives which demonstrate CDK1 and CDK2 antiproliferative activities and are useful as anti-cancer agents....

20060084675 - Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and artesunate combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20060084676 - 3-aryl--3-methyl-quinoline-2, 4-diones, preparation method thereof, and pharmaceutical composition containing the same: The present invention relates to compounds of 3-aryl-3-methyl-quinoline-2,4-diones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of 3-aryl-3-methyl-quinoline-2,4-diones according to the present invention may be valuably used for treatment of a...

20060084678 - Methods for identifying and using marr family polypeptide binding compounds: Methods for identifying MarR family inhibiting compounds are described. The methods include the use of computer aided rational based drug design programs and three dimensional structures of MarR family polypeptides....

20060084677 - Quinoline derivatives as anti-inflammatory agents: wherein A is a CH2, CH(OH), C(O), C═NOR4, NR5, O, S, S(O), or S(O)2, and the other substituents are as defined in the specification; or prodrugs, individual isomers, mixtures of isomers, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their...

20060084679 - Quinoline derivatives as h3r inverse agonists: e

20060084680 - Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation: This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation....

20060084681 - Substituted pyrazoles, compositions containing such compounds and methods of use: The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus....

20060084682 - Thrombopoietin mimetics: Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected...

20060084683 - Method for preventing the onset of asthma: The present invention relates to a method for preventing the onset of asthma which comprises administering to a patient a therapeutically effective amount of cetirizine, an individual optical isomer thereof or a pharmaceutically acceptable salt thereof....

20060084685 - Ophthalmological use of roflumilast for the treatment of diseases of the eye: A pharmaceutical preparation comprising roflumilast for treatment of a disease of the eye is described....

20060084684 - Topically applicable pharmaceutical preparation: A topical pharmaceutical preparation for administering a slightly soluble PDE 4 inhibitor that has a surprisingly good systemic bioavailability is described....

20060084686 - Methods of food intake management: Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The...

20060084687 - Indole and benzimidazole derivatives: The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula:...

20060084688 - Aromatic sulfone hydroxamic acid metalloprotease inhibitor: A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a...

20060084689 - Thiazole-amine compounds for the treatment of neurodegenerative disorders: wherein R1, R3, R4, R5, R6 and R7 are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods of treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds...

20060084690 - Isoxazole derivatives: Y is a group of the formula: —OR3 (wherein R is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted acyl group) or an optionally esterified or amidated carboxyl group, or a salt thereof or a prodrug thereof has a superior insulin...

20060084691 - Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor: The present invention provides a method for treating tumors or tumor metastases in a patient, comprising administering to the patient simultaneously or sequentially a therapeutically effective amount of an EGFR kinase inhibitor and bortezomib combination, with or without additional agents or treatments, such as other anti-cancer drugs or radiation therapy....

20060084692 - Treatment of bipolar disorders and associated symptoms: e

20060084693 - Benzofuran oxyethylamines as antidepressants and anxiolytics: Novel benzofuranoxyethylamines of the formula (1), in which R1, R2, R3, R4, m and n have the meanings indicated in Patent Claim (1), which have a strong affinity to the 5 HT1A receptors and/or 5HT1D receptors. The compounds inhibit serotonin reuptake, exhibit serotonin-agonistic and -antagonistic properties and are suitable as...

20060084694 - Ligand-dependant activation of nur77 and uses thereof: The present invention provides a method for inducing ligand-dependant Nur77 activation in a cell by contacting the cell with an effective dose of an agonist of Nur77. Also provided is a method for treating a mammal having a disease affected by modulation of Nur77 activity as well as a method...

20060084695 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase: The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well...

20060084696 - Compounds and therapies for the prevention of vascular and non-vascular pathologies: The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical...

20060084698 - Methods for preparation and use of psorospermin analogs: Psorospermin is a cytotoxic dihydrofuranoxanthone that has found to exhibit significant activity against various tumor cell lines. Unfortunately, psorospermin is no longer readily available from its natural plant source. The present invention is directed to a method for preparing psorospermin and psorospermin analogs. Methods are also disclosed for utilizing psorospermin...

20060084697 - Pi3k antagonists as radiosensitizers: A method for increasing radiosensitivity of a target tissue in a subject via administration of a PI3K antagonist to a target tissue in a subject. Also provided are methods for suppressing tumor growth and for inhibiting tumor blood vessel growth via administration of a PI3K antagonist....

20060084699 - Novel arylsulphonamide derivatives and use thereof as therapeutic agents: The present invention relates to novel arylsulphonamide compounds, defined by formula I and the description, as well as their method of preparation and their therapeutic use....

20060084700 - Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract: This invention describes the use of beta-3-adrenoceptor agonists for the treatment of disorders associated with the prostate. These include disorders like those occurring in a prostatitis, where attributable to inflammatory processes or chronic irritation, or disorders like those associated with benign changes of the prostate. The invention is particularly suitable...

20060084701 - Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy: The present invention relates to compounds being esters of 5-aminolevulinic acids or pharmaceutically acceptable salts thereof, including compounds of formula (I) R22N—CH2COCH2-CH2CO—OR1 (wherein R1 may represent alkyl optionally substituted by hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, oxo or fluoro groups and optionally interrupted by oxygen, nitrogen, sulphur or phosphorus atoms;...

20060084702 - (2s)-2-ethylphenylpropionic acid derivative: [wherein R1 denotes a halogen atom or trifluoromethyl group, R2 denotes a hydrogen atom, halogen atom or trifluoromethyl group, and, when R2 denotes a hydrogen atom, R3 denotes a halogen atom or trifluoromethyl group and, when R2 denotes a halogen atom or trifluoromethyl group, R3 denotes a hydrogen atom, halogen...

20060084703 - Injectable liquid formulation of paracetamol: The invention relates to a novel injectable liquid formulation of paracetamol, comprising an aqueous solvent, a buffer agent with a pKa between 4.5 and 6.5, an isotonic agent and the dimer of paracetamol of formula (I), a method for preparation of said formulation and the use of said dimer for...

20060084704 - Methods and compositions for enhancing degradation of nuclear receptor transcription factors and uses thereof: The present invention includes methods, compositions, cosmetics and pharmaceutical compositions for enhancing the degradation of a nuclear receptor (NR) or a STAT transcription factor protein. The methods, compositions, cosmetics and pharmaceuticals may be used to prevent or treat disorders or medical conditions that are at least in part affected by...

20060079445 - Camkii/calcium channel binding-related compositions and methods: This invention provides a method for determining whether an agent inhibits binding between CaMKII and a Ca+2 channel. Furthermore, this invention provides a method for inhibiting binding between CaMKII and a Ca+2 channel in a cell. Finally, this invention provides methods of treating cardiac arrhythmia and neurological disorders....

20060079448 - Compounds and methods for increasing neurogenesis: The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed....

20060079439 - Elastin prevents occlusion of body vessels by vascular smooth muscle cells: The present invention provides methods and compositions for promoting elastin signaling in smooth muscle cells including vascular smooth muscle cell. The present invention further provides methods of identifying additional agents that promote elasfin signaling....

20060079444 - Human sef isoforms and methods of using same for cancer gene therapy: A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion...

20060079449 - Inhibition of smad3 to prevent fibrosis and improve wound healing: The invention is related to modulation of Smad3 expression to prevent fibrosis and improve wound healing. Aspects of the invention, for example, include approaches to improve wound healing and/or reduce or prevent fibrosis by inhibiting Smad3. Embodiments described herein also include approaches to identify componds that modulate Smad3 expression and...

20060079446 - Methods and compositions for treating hypercholesterolemia: The present invention provides methods and compositions for treating hypercholesterolemia using therapeutic apoE proteins. A therapeutic apoE protein is a naturally-occurring apoE protein (e.g., apoE1, apoE2, apoE2*, apoE2**, apoE3, and apoE4) that has one or more amino acid substitutions in the carboxy-terminal region which, when administered to a mammal having...

20060079443 - Methods and uses of leptin in immune modulation: The present invention describes the use of leptin for the immune modulation of the Th1/Th2 response. One aspect of the invention provides for a shift in the Th1/Th2 cell balance towards pro-inflammatory cytokine producing cells. This shift results from an increase in the levels, expression and/or the activity of leptin....

20060079442 - Methods and uses of leptin in immune modulation and hepatocellular carcinoma: Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed...

20060079441 - Methods of modulating angiogenesis: The present invention relates to methods for modulating angiogenesis. In some embodiments the methods include a step of contacting a cell experiencing or susceptible to angiogenesis with a composition comprising a multi-unit complex that comprises a tRNA synthetase fragment. The multi-unit complex can include two or more monomer units. Two...

20060079447 - Stabilized a-beta protofibrillar aggregates: Described and claimed herein are methods for producing chemically stabilized Aβ protofibrillar aggregates, and compositions made therefrom. Compositions produced are useful in facilitating detailed studies of Aβ protofibril structure, fibril formation, and progression of Aβ related diseases, e.g., Alzheimers disease. In addition, chemically stabilized protofibrillar structures can be used as...

20060079440 - Treatment of hi-virus infections with oxidised blood proteins: The invention relates to the field of medicaments for combating an infection of a host cell by HI viruses and/or for inhibiting binding of an Env protein to a CD4 protein. For these purposes, the invention provides medicaments which comprise oxidized proteins, oxidized peptides and/or peptidomimetics of such oxidized proteins...

20060079451 - Heparin-binding proteins modified with sugar chains, method of producing the same and pharmaceutical compositions containing same: A heparin-binding protein functionalized by covalently bonding thereto a sugar chain, a method for producing the protein and a pharmaceutical composition containing the protein as an active ingredient, as well as a method of functionalizing a natural protein having no sugar chain by covalently bonding thereto a sugar chain....

20060079450 - Hydroxyethyl starch-containing polypeptide compositions: The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures....

20060079457 - Baff, inhibitors thereof and their use in the modulation of b-cell response: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists....

20060079452 - Fuel reforming device: Substances that inhibit the action of the members of the IL-1β/NF-κB pathway can be used for protecting and preserving β-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the...

20060079453 - Hla binding peptides and their uses: Provided herein are peptides in certian pathogens and/or human or murine proteins that are identified as capable of binding one or more MHC molecules and inducing an immume response in a system. Also provided are compositions that include one or more of the peptides and methods for inducing an immune...

20060079454 - Peptide nanostructures and methods of generating and using the same: A tubular or spherical nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino acid....

20060079455 - Peptide nanostructures encapsulating a foreign material and method of manufacturing same: A composition comprising a material at least partially enclosed by a tubular, spherical or planar nanostructure composed of a plurality of peptides, wherein each of the plurality of peptides includes no more than 4 amino acids and whereas at least one of the 4 amino acids is an aromatic amino...

20060079459 - Stabilized compositions comprising tissue factor pathway inhibitor protein or tissue factor pathway inhibitor variant proteins: Stabilized aqueous compositions of tissue factor pathway inhibitor (TFPI) or TFPI variants comprise a solubilizing agent, an antioxidant, and a buffer. The combination of a solubilizing agent and an antioxidant can lead to a significant improvement in the storage life of TFPI or TFPI variant compositions. The solubilizing agent and...

20060079458 - Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality: The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment...

20060079456 - Vasoactive intestinal polypeptide pharmaceuticals: Pharmaceutical compositions relating to vasoactive intestinal polypeptides and methods for the treatment of metabolic disorders, including diabetes, insulin resistance, metabolic acidosis and obesity are presented. Methods of using the vasoactive intestinal polypeptide compositions are also disclosed....

20060079460 - Purified lh: Recombinant human luteinizing hormone (LH) having a specific bioactivity of from 20,522 to 31,229 IU/mg and obtainable from a process for the purification of recombinant LH from a sample of crude recombinant LH in the supernatant of CHO cells which comprises the combined use of ion-exchange chromatography and reverse phase...

20060079462 - Organoselenium compounds for cancer chemoprevention: A compound containing an alkylene selenocyanate or an alkylene isoselenocyanate moiety effective to prevent the occurrence or progression of cancer or a precancerous condition. The compound can be provided and administered in the form of a pharmaceutical composition, a cosmetic, a food additive, supplement, or the like. Methods for synthesis...

20060079461 - Treatment of multiple myeloma by inhibition of p38 map kinase: The present invention provides a method to treat multiple myeloma by the administration of one or more p38 MAP kinase inhibitor(s)....

20060079463 - Anticancer compositions comprising methenamine: The invention is directed to anti-cancer compositions comprising methenamine or its derivatives or conjugates, and to use of such methenamine containing compositions to treat cancer....

20060079464 - Peritoneal dialysate containing taurine: [Purpose] It is an objective of the present invention to provide a stable neutral peritoneal dialysate that contains a substance other than glucose to serve as an osmotic agent. [Means to solve the problem] The peritoneal dialysate of the present invention is stable and can be provided in the form...

20060079465 - 6r-(3,6-dideoxy-l-arabino-hexopyranosyloxy) heptanoic acid, preparation process for the same and dauer effect thereof: The present invention relates to a determination of a stereochemistry, a synthesis and dauer effect of 6R-(3,6-dideoxy-L-arabino-hexopyranosyloxy)heptanoic acid as a pheromone isolated from the Caenorhabditis elegance related to suppress of aging and stress. It becomes possible to develop medical substances using the pheromone relating to aging, stress, metabolism, signal transfer...

20060079466 - Rapamycin carbohydrate derivatives: This invention provides modified rapamycins that have specific monosaccharide(s), oligosaccharide(s), pseudosugar(s) or derivatives thereof attached through a linker to create rapamycin carbohydrate derivatives having enhanced pharmacokinetic and/or pharmacodynamic profiles. For example, administration of the rapamycin carbohydrate derivative results in altered pharmacokinetic profiles and reduced toxicities. Thus, the present invention provides...

20060079467 - Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions: The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds—Free-B-Ring flavonoids and flavans—for use in the prevention and treatment of diseases and conditions associated with mouth, gums and teeth. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic...

20060079468 - Nucleoside compounds for treating viral infections: Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus....

20060079474 - Analogs of trna synthetase fragments and uses thereof: The present invention relates to analogs of tRNA synthetase fragments and various uses thereof. In some embodiments, the tRNA synthetase fragment is a human tRNA synthetase fragment. In some embodiments, the tRNA synthetase fragment is a tryptophanyl tRNA synthetase fragment. The analogs herein can be used to modulate angiogenesis....

20060079469 - Anti-restenosis agent: An anti-restenosis agent comprises a phosphorothioate-modified oligonucleotide includes at least on hairpin loop and a TG sequence. The hairpin loop preferably has the sequence CAG CGA AGC. Especially preferred oligonucleotides are ones which include a sequence selected from TGGGG TGGGG T GGGGT GGGGT CAG CGA AGC (SEQ ED NO: 4)...

20060079470 - Combined dna vaccine and biological modifiers for cancer therapy: The present invention relates to the combination of a DNA vaccination strategy that makes use of a nucleic acid encoding an immunogenic polypeptide, with a non-immunosuppressive inducer of tumor cell differentiation and/or apoptosis or a tumor cell modifier, useful for cancer therapy. Vaccine compositions and kits are provided, as well...

20060079477 - High affinity nucleic acid ligands of complement system proteins: Methods are described for the identification and preparation of high-affinity Nucleic Acid Ligands to Complement System Proteins. Methods are described for the identification and preparation of high affinity Nucleic Acid Ligands to Complement System Proteins C1q, C3 and C5. Included in the invention are specific RNA ligands to C1q, C3...

20060079476 - Method for enhancing production of isoprenoid compounds: The present invention provides methods of producing an isoprenoid or an isoprenoid precursor in a genetically modified host cell. The methods generally involve modulating the level of hydroxymethylglutaryl-CoA (HMG-CoA) in the cell, such that the level of HMG-CoA is not toxic to the cell and/or does not substantially inhibit cell...

20060079475 - Methods and compositions for modulating cardiac contractility: Methods and compositions are provided for modulating cardiac contractility by regulating transcription of the phsopholamban gene using engineered zinc finger proteins....

20060079472 - Methods for treating angiogenesis: The present invention relates to methods for treating an angiogenesis mediated condition. In particular, the present invention relates to the use of a multi-unit complex that includes a tRNA synthetase fragment or a homolog or analog thereof to treat such conditions. In some embodiments, the multi-unit complex is a dimer...

20060079473 - Multi-unit complexes and uses thereof: The present invention relates to a multi-unit complex of a tRNA synthetase fragment. The multi-unit complexes can comprise of two or more monomer units. Two monomer units can be covalently or non-covalently linked. The multi-unit complexes may further be used, for example, in pharmaceutical formulation to modulate angiogenesis....

20060079471 - Snornai-small nucleolar rna degradation by rna interference in trypanosomatids: Polynucleotides and a method suitable for downregulation of small nuclear RNA which can be used to treat diseases associated with activity of small nuclear RNA are provided. Specifically, the present invention can be used to downregulate snoRNA molecules or box H/ACA-containing RNA molecules which are involved in diseases such as...

20060079478 - Anti-cancer phosphonate analogs: The invention is related to phosphorus substituted anti-cancer compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds....

20060079479 - Methods of inducing vasodilation: Provided herein are methods of inducing vasodilation in a subject diagnosed with a need for vasodilation, comprising administering into a blood vessel of the subject a therapeutically effective amount of a composition consisting essentially of adenosine monophosphate in a pharmaceutically acceptable carrier, whereby the administration of the composition induces vasodilation...

20060079480 - Novel antifolate combination therapies: A method of administering an antifolate to a mammal in need thereof, comprising administering an effective amount of said antifolate in combination with a methylmalonic acid lowering agent....

20060079481 - Method of treating/preventing mucositis: A method of treating and/or preventing mucositis which is an inflammation and ulceration of the mucous membranes, typically resulting from a toxic reaction to chemotherapy and/or radiotherapy by the application of water soluble immunomodulatory β-glucan....

20060079482 - Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same: Ophthalmic compositions are provided that include a lubricant, a deturgescent agent, a glycosaminoglycan, and water. Methods of using the ophthalmic compositions are also provided....

20060079483 - Heparin oligosaccharides: The present invention provides composition and methods for the synthesis of low molecular weight heparins and heparinoids. The present invention also provides compositions having substantially homogenous populations of desired heparin molecules, or molecules useful in the synthesis of heparin oligosaccharides....

20060079484 - Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase u inhibitors: which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least...

20060079486 - Lipopolymer conjugates: Conjugates of formula I, below, are useful in biomedicinal applications such as delivery of drugs or labeling moieties or as components of liposomes or micelles. In formula I, A is a hydrophilic polymer, each of L and L′ is independently a linker group, B is a lipid moiety; and Z...

20060079485 - Use of lipid conjugates in the treatment of infection: This invention provides compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating a pathogenic effect on a cell, including, inter alia, infection with intracellular pathogens. Also provided are compounds and methods of use thereof in suppressing, inhibiting, preventing, or treating an infection in a subject....

20060079487 - Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases: Bisphosphonate compounds and related methods of making and using are disclosed, including pyridinium-1-yl, quinolinium-1-yl, and related compounds. The activity of compounds is disclosed in the context of functional assays such as Leishmania major farnesyl diphosphate synthase (FPPS) inhibition, Dictyostelium discoideum growth inhibition, human gamma delta T cell activation, and bone...

20060079488 - Methods of treating and preventing bone loss: Methods of treating and preventing bone loss and/or enhancing bone formation are disclosed. The methods utilize 15-lipoxygenase inhibitors. These molecules can be delivered alone or in combination with agents which inhibit bone resorption or additional agents that regulate calcium resorption from bone or enhances bone accumulation. The invention additionally provides...

20060079489 - Lactose-free, non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine: Stable pharmaceutical compositions of descarboethoxyloratadine (DCL), a metabolic derivative of loratadine, for the treatment of allergic rhinitis and other histamine-induced disorders are disclosed. The compositions are formulated to avoid the incompatibility between DCL and reactive excipients such as lactose and other mono- and di-saccharides. Disclosed compositions include lactose-free, non-hygroscopic and...

20060079490 - Method of treatment of type i diabetes: A method of delaying the onset or reducing the severity of diabetes in a human patient is disclosed. In one embodiment, the invention comprises the step of orally administering to the human patient an effective amount of a vitamin D compound such as the onset of diabetes or diabetes symptoms...

20060079491 - Method of female hormonal contraception using a fixed extended cycle hormonal preparation containing dienogest and ethinyl estradiol: The fixed extended cycle method of female hormonal contraception includes continuous daily administration of daily dosage units of a monophasic preparation to a woman over a time period of n×21 days, wherein n=2, 3, 4 or 5, immediately followed by a seven-day pill-break in which the monophasic preparation is not...

20060079492 - Compositions and treatment methods: The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method....

20060079493 - Methods for treating genetically- defined proliferative disorders with hsp90 inhibitors: The invention relates generally to methods of treating cell proliferative diseases with HSP90 inhibitors and, depending on the specific aspect and embodiment(s) claimed, to the treatment of proliferative diseases that are associated with fusion proteins, e.g., bcrabl, or mutant proteins or cellular protein isoforms, e.g., mutant forms of p53....

20060079494 - Specific kinase inhibitors: Resorcylic acid lactones having a C5-C6 cis double bond and a ketone at C7 and other compounds capable of Michael adduct formation are potent and stable inhibitors of a subset of protein kinases having a specific cysteine residue in the ATP binding site....

20060079495 - Diagnosis and treatment system for \"reward deficiency syndrome\" (rds) and related behaviors: The present invention relates to a kit and an intravenously administrable preparation, both with a signal transmitter precursor, an enhancer of precursor uptake, and an inhibitor of neurotransmitter reuptake or signal transmitter catabolism. The kit also contains an appropriate swab for obtaining oral cells suitable for allelic analysis. The intravenous...

20060079496 - Agglomerates by crystallisation: The present invention describes novel agglomerates in crystalline form of β-lactum compounds, Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one β-lactum compound in a solvent is mixed with one or more anti-solvents has been described....

20060079497 - Lavendamycin analogues and methods of synthesizing and using lavendamycin analogues: Lavendamycin analogues, methods for their synthesis, and methods for their use in the treatment of diseases such as cancer and HIV infection are described....

20060079498 - Therapeutic compounds: v

20060079499 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds: Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical...

20060079500 - Medicament and method for reducing alcohol and/or tobacco consumption: The present invention relates to a medicament for treating addiction craving which is characterized in that the medicament consists of a combination of two administration forms, one of the administration forms continuously releasing at least one modulator of nicotinic receptors and the other administration form enabling a rapid entry of...

20060079501 - Compositions of an anticonvulsant and mirtazapine to prevent weight gain: Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further...

20060079502 - Pharmaceutical compositions: Oral dosage forms comprising oxcarbazepine which when administered to a patient display no food effect....

20060079504 - Selected cgrp antagonists, processes for preparing them and their use as pharmaceutical compositions: a

20060079505 - Modulators of muscarinic receptors: The present invention relates to modulators of muscarinic receptors. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases....

20060079503 - Thiazolidinones and the use therof as polo-like kinase inhibitors: e

20060079506 - Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors: wherein said C6-12cycloalkyl or monovalent radical may optionally be substituted with one, or where possible two, three or more substituents selected from the group consisting of C1-4alkyl, C1-4alkyloxy, halo or hydroxy; Q represents Het1 or Ar2 wherein said C3-8cycloalkyl, Het1 or Ar2 are optionally substituted with one or where possible...

20060079507 - Substituted imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine derivatives: R is hydrogen, lower alkyl, lower alkyl substituted by halogen, heteroaryl, —(CH2)nO-lower alkyl, —NH-lower alkyl, cycloalkyl or aryl, and n is 0, 1, 2 or 3; and with their pharmaceutically acceptable acid addition salts. The invention also provides novel compounds of formula I-A and pharmaceutical compositions containing them. The most...

20060079511 - 7,8-disubstituted pyrazolobenzodiazepines: wherein R1, R2, R3, R4, and R5 are described herein. The invention also provides syntheses for preparation of such compounds and pharmaceutical compositions containing them. The invention further provides methods for inhibiting kinases, in particular CDK2, for inhibiting angiogenesis, and for treating cancers, in particular breast, colon, prostate, and lung...

20060079508 - Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions: This invention relates to methods of inhibiting growth and/or proliferation of a neoplastic cell, and methods of treating neoplasms using the farnesylated dibenzodiazepinone compound of Formula I. The invention includes pharmaceutical compositions comprising the compound of Formula I:...

20060079509 - Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals: The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions....

20060079512 - Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals: The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, to pharmaceutical compositions comprising them and to methods of treating neoplastic conditions....

20060079510 - Use of parp-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis: Method and composition for protecting tumorcidal lymphocytes including cytotoxic lymphocytes and NK cells from apoptosis and down regulation are provided. The method and composition include the administration of an effective amount of a PARP-1 inhibitor to a population of cytotoxic T lymphocytes and NK cells in the presence of monocytes...

20060079515 - Method for the treatment of polycystic kidney disease: The present invention provides a method for treating, inhibiting the progression of, or eradicating polycystic kidney disease of in a patient in need thereof which comprises providing to said patient an effective amount of a TACE inhibitor compound in combination with an effective amount of a Src kinase inhibitor, a...

20060079514 - Methods and compositions including methscopolamine bromide: Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine bromide is the preferred anticholinergic agent. The sedative agent may be chlordiazepoxide hydrochloride or diazepam. Various methods using the compositions...

20060079513 - Methods and compositions including methscopolamine nitrate: Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine nitrate is the preferred anticholinergic agent. The sedative agent may be a benzodiazepine or a barbiturate. Particularly, the sedative agent...

20060079516 - Highly concentrated stable meloxicam solutions: Aqueous cyclodextrin-free solution of meloxicam for administration by oral or parenteral route, containing a pharmacologically acceptable meloxicam salt of an organic or inorganic base and one or more suitable excipients, the content of dissolved meloxicam salt being more than 10 mg/mL. The formulation according to the invention has a shelf-life...

20060079517 - Reverse-turn mimetics and methods relating thereto: wherein A, B, X, R1, and R5 are as defined herein. Such compounds have utility over a wide range of fields, including use as diagnostic and therapeutic agents. In particular, compounds of this invention are useful in pharmaceutical compositions as anti-inflammatory agents as well as inhibitors of central nervous disorders....

20060079518 - Novel tyrosine kinase inhibitors: e

20060079519 - Anti-cytokine heterocyclic compounds:

20060079520 - Sulfonamide peri-substituted bicyclics for occlusive artery disease:

20060079521 - Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof: Novel compounds having hydroxybenzoimidazole carboxylic amide are useful for inhibiting glycogen synthase kinase 3β (GSK-3β)....

20060079522 - Amino substituted aryloxybenzylpiperidine derivatives: This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically...

20060079523 - Arylthiobenzylpiperidine derivatives: This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount...

20060079524 - Amino substituted aryloxybenzylpiperidine derivatives: This invention is directed to Amino substituted Aryloxybenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically...

20060079525 - Morpholin-acetamide derivatives for the treatment of inflammatory diseases: i

20060079526 - Heterocyclic compounds and methods of use: Heterocyclic compounds derived from benzotriazine, triazines, triazoles and oxadiazoles are disclosed. The methods of synthesis and of use of such heterocyclic compounds are also provided....

20060079527 - Piperazine derivatives having sst1 antagonistic activity: The invention provides compounds of formula (I), wherein X, R1 and R2 are as defined in the description, and their preparation. The compounds of formula (I) are useful as pharmaceuticals....

20060079528 - Carbamic acid compounds comprising a bicyclic heteroaryl group as hdac inhibitors: This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C9-10heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated...

20060079530 - Farnesyl transferase inhibitors: A family of compounds capable of inhibiting the activity of farnesyl transferase....

20060079529 - Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders: This invention relates to the use of compounds capable of inhibiting the activity of a proton-gated cation channel in the treatment of alleviation of diseases or disorders associated with, or mediated by a drop in extra cellular pH....

20060079531 - Pharmaceutically active ornithine derivatives, ammonium salts thereof and methods of making same: The present invention relates to pharmaceutically active ornithine compounds, particularly to pharmaceutically acceptable ammonium salts of Nδ-acyl derivatives of Nα(4-amino-4-deoxypteroyl)-L-ornithine compounds; and methods of treatment and pharmaceutical compositions that utilize or comprise one or more of such ammonium salts. The ammonium salts provided by the invention exhibit superior chemical stability...

20060079533 - Methods of treating alzheimer's disease: Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of 3,4-disubstituted piperidinyl compounds of formula (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined herein....

20060079532 - Use of tetramethylpyrazine in the treatment of brain tumor: The present invention relates to the use of tetramethylpyrazine (TMP) in the treatment of brain tumor....

20060079534 - Cell division inhibitor and a production method thereof: The present invention relates to a cell division inhibitor comprising various dehydrodiketopiperazines such as dehydrophenylahistin, or analogs thereof as an active ingredient, and a dehydrogenase and a method for producing the same inhibitor....

20060079535 - 5-phenoxyalkoxypsoralens and methods for selective inhibition of the voltage gated kv1.3 potassium channel: Compositions of matter comprising 5-phenoxyalkoxypsoralen compounds and their method of synthesis and use. The compounds are useable to treat diseases or disorders in human or animal subjects, including autoimmune diseases. The compounds inhibit potassium channels, including the Kv1.3 channel and at least some of the therapeutic effects of such compounds...

20060079536 - Calcium receptor modulating compound and use thereof: wherein ring A is an optionally substituted 5- to 7-membered ring; Q is C, CR5 or N; R8, R9, R10, R11 and R12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X1, R3, R1, Y and X3 in formula (II)...

20060079537 - 2-substitutued triazolopyrimidines, methods and intermediate products for the production thereof, the use of the same controlling pathogenic fungi, and agents containing said compounds: R3 is cyano, hydroxyl, alkoxy, alkenyloxy, haloalkoxy, haloalkenyloxy, NR1R2 or S(O)nR31, where n and R31 are as defined in the description; Processes and intermediates for preparing these compounds, compositions comprising them and their use for controlling phytopathogenic harmful fungi are described....

20060079538 - Methods for inhibiting angiogenesis: The invention relates generally to methods for inhibiting angiogenesis. More particularly, methods for inhibiting angiogenesis comprise selectively inhibiting phosphoinositide 3-kinase delta (PI3Kδ) activity in endothelial cells. The methods may comprise administration of one or more cytotoxic therapies including but not limited to radiation, chemotherapeutic agents, photodynamic therapies, radiofrequency ablation, anti-angiogenic...

20060079539 - Synergistic combination: The invention relates to the combined administration of PDE inhibitors and β2 adrenoceptor agonists for the treatment of respiratory disorders....

20060079540 - Pde4 and pde3/4 inhibitors for use in the treatment of cachexia: The invention relates to the use of a PDE4 or PDE3/4 inhibitor for the treatment of cachexia....

20060079541 - 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions: e

20060079542 - Compounds and methods for treating insulin resistance and cardiomyopathy: Novel compounds, compositions comprising compounds, and methods for methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular...

20060079543 - Anilino-pyrimidine analogs: v

20060079544 - Medicaments for the prevention or treatment of alveolar pneumonia comprising an anticholinergic: The present invention relates to a method for the prevention or the treatment of alveolar pneumonia comprising administration of a therapeutically effective amount of an anticholinergic 1, medicaments for the prevention or treatment of alveolar pneumonia comprising one or more, preferably one anticholinergic 1, and methods for the preparation of...

20060079545 - Palonosetron for the treatment of chemotherapy induced emeses: Methods and compositions for reducing chemotherapy and radiotherapy induced emises with 5-HT3 receptor antagonists are disclosed, especially with palonosetron....

20060079546 - Aminopiperidine derivatives as antibacterials: Aminopiperidine derivatives of Formula (I) and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man:...

20060079548 - Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use: and to prodrugs or metabolites thereof, or pharmaceutically acceptable salts or solvates of said compounds, said prodrugs, and said metabolites, wherein Z, Y, R11 and R14, R15, R16, and R17 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods...

20060079547 - Thienopyridinone compounds and methods of treatment: The invention relates to 5-HT4 receptor agonists and partial agonists. Novel thienopyridinone compounds and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT4 receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, Parkinson's disease, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, and...

20060079549 - Heterocyclic aromatic compounds useful as growth hormone secretagogues: e

20060079550 - Amino acid derivatives useful for the treatment of alzheimer's disease: The present invention is a method of treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of known compounds of formula (I): wherein R1, R2, R3, R4, W and Cx are herein defined....

20060079551 - Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors: The present application is directed to a method of treating diseases of the central nervous system (CNS) comprising administering to a individual in need of treatment a therapeutically effective amount of an inhibitor of histone deacetylase. In particular embodiments, the CNS disease is a neurodegenerative disease. In further embodiments, the...

20060079552 - 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea salt: The invention relates to 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline salt or a non defined salt hydrate thereof and a process for its preparation. Further, the present invention relates to the use of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as a crystalline salt alone or in combination with other compounds or formulations of said 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as...

20060079553 - Quinoline derivatives as glucokinase ligands: Compounds of formula (I), wherein one of R1 and R2 is selected from a group (IA), ring A is substituted pyridin-z-yl of thiazol-z-yl, the other substituents are as described in the description and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase....

20060079555 - Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof: Compounds of general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, m and n are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain....

20060079554 - Inhibitors of monomine uptake: N,N-disubstituted 4-amino-piperidines of the general Formula (I) are inhibitors of the uptake of serotonin and/or norepinephrine and/or dopamine. As such, they may be useful for the treatment of disorders of the central and/or peripheral nervous system....

20060079556 - N-sulfonylpiperidine cannabinoid receptor 1 antagonists: The present application describes compounds according to Formula I, wherein R1, R2, R3, R4, X and Y are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods...

20060079557 - Sulfamoyl benzamide derivatives and methods of their use: Novel sulfamoyl benzamide compounds, pharmaceutical compositions containing the sulfamoyl benzamide compounds, and methods of their pharmaceutical use are disclosed. In certain embodiments, the sulfamoyl benzamide compounds are agonists and/or modulating ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, inflammation, auto-immune diseases,...

20060079558 - R-isomer of 2-{2[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetics: The present invention relates to the R-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep....

20060079559 - S-isomer of 2-{2[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetics: The present invention relates to the S-isomers of anesthetic compounds, the methods of treatment therewith, the compounds being useful for inducing local anesthesia, analgesia and sleep....

20060079560 - Crystalline form of omeprazole: A novel crystalline form of the substrate known under the chemical name 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole, and having the generic name omeprazole, hereinafter referred to as omeprozole form C, is disclosed. Further, a process for the preparation of omeprazole form C, a pharmaceutical formulation containing omeprazole form C in admixture with pharmaceutically acceptable...

20060079561 - Insecticidal anthranilamides: A, B, J, R1, R2, R3 and R4 and n are as defined in the disclosure. Also disclosed are methods for controlling arthropods comprising contacting the arthropods or their environment with an arthropodicidally effective amount of a compound of Formula 1 and compositions containing the compounds of Formula 1....

20060079562 - Heterocyclic aromatic compounds useful as growth hormone secretagogues:

20060079563 - Cyclic protein tyrosine kinase inhibitors: Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders....

20060079564 - Indazole benzimidazole compounds: v

20060079565 - Amino acid composition and supplementary liquid containing the same: An amino acid composition comprises alanine, arginine, aspartic acid, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and glutamine. The amino acid composition of the present invention has such an effect that it can improve the action of promoting the process wherein the...

20060079566 - Pdk-1/akt signaling inhibitors: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1-C4 alkyl,...

20060079567 - Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators: The present invention generally relates to a series of compounds, to pharmaceutical compositions containing the compounds, and to use of the compounds and compositions as therapeutic agents. More specifically, compounds of the present invention are hexahydroazepinoindole and octahydroazepinoindole compounds. These compounds are serotonin receptor (5-HT) ligands and are useful for...

20060079568 - Inhibition of atherosclerosis by diindolylmethane analogs: Diindolylmethane analogs such as 1,1-bis(3′-indolyl)-1-(p-substituted phenyl)methanes can be used to treat atherosclerosis and other vascular disease states. The analogs have been shown to display antiinflammatory effects in endothelial cells, suggesting their clinical applicability....

20060079569 - Antidepressant oral liquid compositions: The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used...

20060079570 - Alpha-aminoamide derivatives useful as antimigraine agents: α-Aminoamide derivatives useful as antimigraine agents, particularly for the treatment of head pain conditions such as migraine, cluster headache or other severe headache, are disclosed. The antimigraine agents of the invention are able to reduce or even stop the pain deriving from such conditions without, virtually, any side effects....

20060079571 - Semisynthesis process for the preparation of 10-deacetyl-n-debenzoyl-paclitaxel: x

20060079572 - Novel bioactive substance: The present invention provides a novel bioactive substance having an antitumor activity and a process for producing it, and a medical use thereof. Namely, it provides a 12-membered ring macrolide compound represented by the following formula obtained from the incubation solution of Streptomyces sp. Mer. 11107 or a variant thereof,...

20060079573 - Methods and compositions for preventing vasospasm: Methods and compositions for preventing or reducing vascular smooth muscle contraction are provided. Exemplary compositions comprise an MLCK inhibitor, for example wortmannin, in an amount effective to prevent or reduce vascular smooth muscle vasospams by about 90% for at least about 20 minutes. Methods for identifying other modulators of MLCK...

20060079574 - Methods of treating mental diseases, inflammation and pain: t

20060079575 - Gamma-butyrolactone compound and pharmaceutical composition thereof: wherein R1, R2, R3, R4, and R5 are selected from a hydrogen atom, a halogen atom, a hydroxyl group, a mercapto group, an amino group, an alkoxy group, and a nitro group. The γ-butyrolactone compound and pharmaceutical composition thereof butyrolactone have inhibitory effects on hepatoma, ovarian cancer, breast cancer, lung...

20060079576 - Estrogenic compounds as anti-mitotic agents: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods....

20060079577 - Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases: The use of lipoxin analogs for the treatment or prevention of asthma and asthma related diseases is described. In particular, acetylenic lipoxin analogs are effective for the treatment and prevention of eosinophil recruitment involved with the inflammation processes associated with asthma, asthma like conditions, and lung injuries associated from airway...

20060079578 - Pharmaceutical formulations of amyloid inhibiting compounds: Therapeutic formulations and methods for inhibiting amyloid deposition in a subject, whatever its clinical setting, are described. Therapeutic formulations and methods for preventing or treating amyloidosis and/or amyloid-related disease are also described....

20060079579 - Combinations of valsartan with cox-2 inhibitors: The invention relates a pharmaceutical composition comprising a combination of (i) the AT 1-receptor blocker valsartan or a pharmaceutically acceptable salt thereof and (ii) a COX-2 inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a...

20060079580 - Production of mutant strain of aspergillus fumigatus, method of assay for inhibiting siderophore biosynthesis and diagnostic method for detecting likely aspergillus fumigatus infection: This application relates to the production and characterization of a mutant strain of Aspergillus fumigatus. The application also relates to a method for inhibiting siderophore biosynthesis in Aspergillus fumigatus and an assay for identifying drug candidates or other agents having potential inhibitory activity. The method may comprise, for example, the...

20060079581 - Polymorphs of atomoxetine hydrochloride: The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides pharmaceutical compositions that comprise atomoxetine hydrochloride Form B, Form C, or mixtures thereof that can...

20060079582 - Memantine for the treatment of childhood behavioral disorders: The present invention provides a method for the treatment of individuals diagnosed with a childhood behavioral disorder such as autistic spectrum disorders or combined type Attention-Deficit/Hyperactivity Disorder (ADHD) by administering an effective amount of memantine....

20060074011 - Compositions providing for increased igf-i solubility: Novel IGF-I compositions are described. The compositions include a solubilizing compound comprising a guanidinium group that provides for IGF-I compositions in which IGF-I is highly soluble at pHs of about 5.5 or greater and at refrigerated temperatures....

20060074008 - Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease: Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions...

20060074010 - Method and apparatus for purifying pharmaceutical compositions using supercritical fluids: The present invention provides a method and an apparatus for removing impurities from biodegradable polymers and/or pharmaceutical compounds. In accordance with the method, a stream of supercritical fluid and, optionally, a modifying co-solvent, is used to dissolve the impurities. The pressure and temperature of the supercritical fluid or supercritical fluid/co-solvent...

20060074009 - Natriuretic compounds, conjugates, and uses thereof: Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved...

20060074012 - Treatment of gestational diabetes: Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels....

20060074007 - Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2; compositions and uses thereof: Novel genes expressed selectively by long-term dendritic cell (DC) lines (XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a...

20060074013 - Multiple agent diabetes therapy: A pharmaceutical composition includes at least two of agents I)-iii), wherein agent i) is selected from the group consisting of an insulin, an insulin analog, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, agent ii) is selected from the group consisting of...

20060074014 - Dalbavancin compositions for treatment of bacterial infections: The invention provides methods and compositions for treatment of bacterial infections. The composition may be a combination of factors, which include A0, A1, B1, B2, C0, C1, isoB0, and MAG, in the presence of low level solvent. Methods of the invention include administration of dalbavancin formulations for treatment of a...

20060074015 - Novel cyclosporin alkynes and their utility as pharmaceutical agents: e

20060074017 - Active complex of alpha-lactalbumin (hamlet) and cofactor: The use of a biologically active complex of α-lactalbumin, selected from HAMLET (human α-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous...

20060074023 - Angiogenesis associated proteins, and nucleic acids encoding the same: An isolated polypeptide having at least 80% sequence identity to the sequence SEQ ID NOS:2, 4, 6, 8, 10, 12, 14 or 16, and polynucleotides encoding the same, are useful for modulating angiogenesis....

20060074019 - Human growth hormone treatment methods: New methods for developing dosing formulas that allow the determination of appropriate dosage regimens for human growth hormone (hGH) compounds; methods for using such formulas to calculate individualized hGH compound dosage regimens; methods for treatment of hGH-responsive syndromes in patients using such determined regimens; systems, devices, and computer-readable media comprising...

20060074020 - Inhibition of angiogenesis by neutrophil alpha-defensins: The present invention relates to the inhibition of angiogenesis by neutrophil alpha-defensins. Further, the present invention relates to methods involving the inhibition of endothelial cell adhesion to the extracellular matrix, endothelial cell apoptosis, and endothelial cell angiogenesis.mediated by alpha-defensins. b) instructions for the use of said α-defensin for the purpose...

20060074018 - Methods of diagnosing & treating diabetes and insulin resistance: The present invention provides compositions and methods for diagnosing and treating diabetes and insulin resistance. In particular, the invention provides methods of identifying modulators of the polynucleotides or polypeptides of the invention and using those modulators to treat diabetes, as well as methods of diagnosing diabetes by measuring the levels...

20060074016 - Multifunctional context-activated protides and methods of use: This invention is directed to multifunctional, context-activated protides that have two or more effectors with individually distinct biological functions and one or more corresponding activator sites that can each initiate or amplify the biological function of one or more effectors upon context-activation. The context-activated protides of the invention are useful...

20060074021 - Novel antimicrobial agents: A novel class of antimicrobial polymeric agents which are designed to exert antimicrobial activity while being stable, non-toxic and avoiding development of resistance thereto and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and a method of treating medical conditions associated with pathological microorganisms,...

20060074022 - Prevention of primary sjogren's syndrome by ica69 deficiency: This invention relates to identification of an autoantigen implicated in the development and progression of Sjögren's Syndrome (pSS); particularly to the disease modifying effect of creating a deficiency in the ICA69 autoantigen; and most particularly to development of diagnostic and therapeutic avenues, means for the differential diagnosis of pSS versus...

20060074025 - Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability: What is described is a pharmaceutical formulation for intranasal delivery of glucagon-like protein-1 (GLP-1), comprising an aqueous mixture of GLP-1, a solubilizing agent, a chelator, and a surface active agent....

20060074024 - Treatment of congestive heart failure: A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced...

20060074026 - Therapeutic agents and methods for cardiovascular disease: The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at...

20060074027 - Sustained-release preparations: A sustained release preparation comprising a combination of a microcapsule which gradually releases a GnRH agonist or a salt thereof for a long term, and a microcapsule which gradually releases a GnRH agonist or a salt thereof for a short term....

20060074028 - Reducing axon degeneration with proteasome inhibitors: Reduced degeneration of an axon predetermined to be subject to degenerative neuropathy in a term patient is effected by contacting the axon in situ with an effective amount of a ubiquitin-proteasome system (UPS) inhibitor sufficient to reduce degeneration of the axon; and detecting a resultant reduction in the degeneration of...

20060074030 - Cyclopamine analogues and methods of use thereof: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of...

20060074031 - D-pyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture: e

20060074029 - Topical antimicrobial composition having improved moisturization properties: The invention described herein provides an extended resident topical antimicrobial composition comprising an active antimicrobial and moisturizing ingredients that meets antimicrobial efficacy requirements and improves the condition of the user's skin as well. The composition of the invention achieves desired antimicrobial efficacy and therapeutic effect and still exhibits a relatively...

20060074032 - Synthesis and separation of optically active isomers of erythromycin and their biological actions: The present invention provides methods for purifying and using optically active isomers of erythromycin as well as compositions comprising such optically active isomers. Such optically active isomers having desired actions as an antibiotic substantially separable from undesirable effects on GI motility and the cardiac potassium channels such that the cardiac...

20060074036 - Agents for gene therapy of cerebrovascular disorders: The present invention provides novel methods for treating cerebrovascular disorders, in which HGF is overexpressed by introducing an HGF gene. The methods of this invention using an HGF gene enable active treatment of cerebrovascular disorders, such as cerebral infarction, by gene transfer, and enable the maintenance of neuronal function and...

20060074041 - Antisense and antigene therapeutics with improved binding properties and methods for their use: The present invention is directed to novel nucleic acid molecules and methods for their use. More specifically, the novel nucleic acid molecules of the present invention are capable of tightly and specifically interacting with a target molecule of interest not only through standard Watson-Crick base pairing, but also through additional...

20060074043 - Antisense modulation of matrix metalloproteinase 1 expression: Antisense compounds, compositions and methods are provided for modulating the expression of matrix metalloproteinase 1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding matrix metalloproteinase 1. Methods of using these compounds for modulation of matrix metalloproteinase 1 expression and for treatment of diseases associated with...

20060074034 - Cobalamin mediated delivery of nucleic acids, analogs and derivatives thereof: This invention is in the area of cobalamin-mediated delivery of nucleic acids and analogs and derivatives thereof to a host to affect gene expression....

20060074035 - Dinucleotide inhibitors of de novo rna polymerases for treatment or prevention of viral infections: Contemplated dinucleotide compounds have a general structure of A-B and inhibit synthesis of an RNA-dependent polymerase that initiates RNA replication de novo. In preferred dinucleotides, A comprises a purine or modified purine heterocyclic base and B comprises a pyrimidine or modified pyrimidine heterocyclic base....

20060074038 - Her-2 neu dna vaccine having anti-cancer activity: The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic...

20060074042 - Highly hypoxia-specific gene expression system for ischemic gene therapy: Compositions and methods for treating ischemic diseases, such as ischemic heart disease, are disclosed. Plasmid pEpo-SV-VEGF-EpoUTR comprises an erythropoietin enhancer and an erythropoietin 3′ untranslated region operably coupled to a vascular endothelial growth factor (VEGF) coding segment. High expression of VEGF under hypoxic conditions is obtained. Similar plasmids, with anticancer...

20060074039 - Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides: The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating inflammatory arthropathies by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide....

20060074044 - Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides: The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof the correspond to a novel human secreted stem cell growth factor-like polypeptide. These polypeptides comprise nucleic acid sequences isolated from cDNA libraries prepared from human fetal liver spleen, ovary, adult brain, lung tumor, spinal...

20060074033 - Secreted and transmembrane polypeptides and nucleic acids encoding the same: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides...

20060074040 - Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy: The invention provides optimized methods and compositions for enhancing the immune response caused by immunostimulatory compounds used for the treatment of disease such as, but not limited to, treatment of cancer, autoimmune disorders, asthma, respiratory allergies, food allergies and infectious diseases in a patient. The optimized methods according to the...

20060074037 - Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins: A method is disclosed for producing a polypeptide with a modified activity or stability, by replacing an arginine residue capable of being ADP-ribosylated with a tryptophan or a phenylalanine. In one embodiment, compositions are provided that include polypeptides, such as alpha defensin, with arginine-to-tryptophan or arginine-to-phenylalanine substitutions, where the arginine...

20060074045 - Vector for transfection of eukaryotic cells: Vectors comprising a nucleic acid, a nucleic acid binding polymer, a vesicle and a membrane active polypeptide are described. Preferred vectors facilitate transfection and/or reduce cytotoxicity. Methods of making the vectors and methods of using the vectors to transfect cells and/or treat a patient in need of gene therapy are...

20060074047 - Method of treating inflammation with inhibitors of sialyl transferases: Provided herein are a methods of reducing a level of activity of a sialyl transferase enzyme, a sialidase enzyme or a combination thereof using inhibitors of these enzymes, for example specific inhibitory compound or antibodies directed against the enzymes. The methods are effective to treat an inflammatory disease or disorder...

20060074046 - Oral administration of decitabine salt: The present invention relates to salts of decitabine as well as methods for synthesizing the salts described herein. Pharmaceutical compositions and methods of using the decitabine salts are also provided, including methods of orally administering the salts or pharmaceutical compositions thereof to treat conditions, such as cancer and hematological disorders....

20060074050 - Composition and method for treating hyperproliferative diseases: The present invention is directed to methods and compositions for treatment of hyperproliferative diseases. The composition of the invention comprises a carbohydrate having a backbone comprising polygalacturonan and a ligand of peripheral benzodiazepine receptor. The present compositions and methods are used to treat various cancers and other diseases where cells...

20060074052 - Compositions and methods for treating mammals with modified alginates and modified pectins: A modified alginate and/or modified pectin composition and method for preventing and/or treating diseases and/or conditions caused by circulating agents such as poisonous heavy metals, environmental toxins, calcium and cholesterol, is provided. The composition includes a modified alginate having a molecular weight of no more than 40,000 daltons and/or a...

20060074048 - Mixed esters of hyaluronic acid with retinoic and butyric acids: The present invention relates to mixed esters of hyaluronic acid, wherein the hydroxyl groups are partially esterified with retinoic and butyric acids. These mixed esters are characterized by specific degrees of esterification and by a high ratio between the degree of substitution with butyric acid and retinoic acid. They exhibit...

20060074051 - Therapeutic stem cell growth factor composition, anti-inflammatory composition, and uses thereof: The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a...

20060074049 - Use of heparinoids for treatment and prevention of dementia: Methods for treating, preventing, or reducing development of non-traumatic interneuron pathologies are described herein. Also described are methods for treating or preventing dementia (e.g., dementia associated with HIV, AIDS, or Alzheimer's disease)....

20060074053 - Ophthalmic solution containing quinolone antimicrobial compound: The present invention provides an ophthalmic solution containing as the active ingredient a quinolone antimicrobial compound, wherein at least one member selected from the group consisting of water-soluble vinyl polymeric compounds and water-soluble cellulose derivatives is formulated into the ophthalmic solution to prevent the quinolone antimicrobial compound from precipitating when...

20060074054 - Phospho-indoles as hiv inhibitors: 3-phosphoindole compounds for the treatment of retroviral infections, and particularly for HIV, are described. Also included are compositions comprising the 3-phosphoindole derivatives alone or in combination with one or more other anti-retroviral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds....

20060074056 - Inhibitors of vegf receptor and hgf receptor signaling: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions...

20060074057 - Use of chenodeoxycholic acid for reducing adipose tissue: Use of chenodeoxycholic acid is disclosed to reduce adipose tissue and thereby reduce weight in mammals. The chenodeoxycholic acid can be administered orally through the use of a tablet, pill, capsule or liquid suspension....

20060074058 - Combination of dpp iv inhibitor and a cardiovascular compound: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and a cardiovascular compound (being different from a statin) or a pharmaceutically acceptable salt thereof. The present invention furthermore relates to the...

20060074060 - Compound: There is provided a compound of Formula (I) wherein (I) R2 is selected from (i) an alkyloxyalkyl group (ii) a nitrile group, and wherein R2 is capable of forming a hydrogen bond (iii) alkylaryl group, wherein the aryl group is substituted by other than a C1-10 group (iv) alkenylaryl group...

20060074059 - Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one: The present invention provides stable particles of 3a-hydroxy-21-(1′-imidazolyl)-3β-methoxymethyl-5a-pregnan-20-one (Compound I), which possess and retain a shape and size appropriate for handling and manufacture of large-scale pharmaceutical preparations, even in the absence of further milling. Further provided is a method for obtaining such reproducible, stable particles by subjecting crude Compound I...

20060074061 - Formulations of glucocorticoids to treat pathologic ocular angiogenesis: Formulations of glucocorticoids alone and in combination with anecortave acetate are useful for preventing and treating pathologic ocular angiogenesis and associated edema...

20060074062 - Substituted porphyrins: The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such...

20060074063 - Pharmacological agent and method of treatment: An antiproliferative, antiinflammatory, antiinfective, immunization agent of a metal ion chelating agent such as picolinic acid, analogs or derivatives thereof, and methods of using the same. The agents chelate metals in metal containing protein complexes and enzymes required for growth, replication or inflammatory response. The preparations can be administered systemically...

20060074064 - Tricyclic 6-alkylidene-penems as beta-lactamase inhibitors: The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof....

20060074065 - 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors: wherein: R1—R4 and A have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting β-lactamase enzymes, for enhancing the activity of β-lactam antibiotics, and for treating β-lactam resistant bacterial infections in a mammal. The invention also provides pharmaceutical compositions, processes for preparing...

20060074066 - Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease: This invention is directed to the use of an inhibitor of cathepsin-S or -B, or composition thereof, to treat or prevent chronic obstruction pulmonary disease, or physiological condition associated therewith. Such a therapy would occur using at least one of such inhibitors alone or in combination with the other, or...

20060074067 - N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof: Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are N-aryl or heteroaryl azaspiroalkene/alkane compounds, prodrugs or metabolites of these compounds, or pharmaceutically acceptable salts thereof. The aryl group can be a phenyl ring or a five- or six-membered heterocyclic ring (heteroaryl)....

20060074070 - Gram-positive carbapenem antibacterials and processes for their preparation: The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of...

20060074071 - Substituted arylamides: Substituted benzamide compounds are provided along with methods for the use of those compounds for treating cancer....

20060074068 - Chemical compounds with dual activity, processes for their preparation and pharmaceutical compositions: The present invention concerns chemical compounds combining affinity and antagonism against the human m3 muscarinic receptor with activity as selective phosphodiesterase IV (PDE IV) inhibitors, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals....

20060074069 - Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists: In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P by blocking the NK receptors, the compounds according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of...

20060074072 - Carboxamide derivatives and their use as factor xa inhibitors: Novel compounds of the formula (I) in which R1, D, X, W, Y and T have the meaning indicated in Patent Claim (1), e.g. (II), are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours....

20060074073 - Therapeutic combinations comprising poly (adp-ribose) polymerases inhibitor: v

20060074074 - Tricyclic triazolobenzazepine derivatives, process for producing the same, and antiallergic agents:

20060074075 - Modulators of atp-binding cassette transporters: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators....

20060074076 - Heterocyclic derivatives for modulation of calcium channels: Heterocyclic derivatives act as Ca channel antagonists. The compositions are useful for treating or relieving Ca channel mediated conditions....

20060074077 - Pharmaceutical composition for the treatment of athetoid movement: A pharmaceutical composition for the treatment of athetoid movement comprising clonazepam or pharmaceutically acceptable salts thereof as an active ingredient are provided, and are useful for the treatment of athetoisis without any tolerance and adverse effect....

20060074078 - Product comprising a transduction inhibitor of heterotrimeric g protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer: A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one other anti-cancer agent selected from the group consisting of prenyltransferase inhibitors, taxol and its analogues, gemcitabine and camptothecin and its analogues, administered...

20060074079 - Solid pharmaceutical formulations comprising diacereine and meloxicam: This invention relates to formulations in solid pharmaceutical forms containing diacereine and meloxicam. The present invention provides novel formulations comprising: (a) Diacereine, (b) Meloxicam, (c) one or more anti-adherent agents, (d) one or more disintegrating agents, (e) one or more binder agents, (f) one or more lubricants, (g) one or...

20060074080 - Combination product comprising melagatran and an anti-arrhythmic oxabispidenes: There is provided a combination product comprising: (1) melagatran or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof)...

20060074081 - Progesterone receptor structure: This invention relates to progesterone receptor/ligand complexes, and related methods and software systems....

20060074082 - (arylamidoaryl)cyanoguanidine compounds: i

20060074083 - Cyclic and acyclic propenones for treating cns disorders: The invention relates to novel cyclic and non-cyclic propenone derivatives as well as their pharmaceutically acceptable slats. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are useful as medicaments....

20060074084 - Inhibitors of soluble adenylate cyclase: The invention relates to compounds of general formula I as well as their production and use as a medication....

20060074085 - N-sulfonylurea apoptosis promoters: e

20060074086 - Phenyl derivatives and methods of use: Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be useful, inter alia, for treating and/or preventing pain, gastrointestinal disorders, genitourinary disorders, inflammation, glaucoma, auto-immune diseases, ischemic conditions, immune-related...

20060074087 - 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes: The present invention is directed to 3-amino-4-phenylbutanoic acid derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also...

20060074088 - Dihydropteridinones for the treatment of cancer diseases: optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation...

20060074089 - Quinolone analogs: The present invention provides quinolone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing quinolone analogs, and methods of using the same....

20060074090 - 1,2,5-thiadiazol-3-yl-piperazine therapeutic agents useful for treating pain, depression and anxiety: (wherein X, R1, R3, R4, and R5 are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Thiadiazolylpiperazine Compound”), pharmaceutical compositions comprising a Thiadiazolylpiperazine Compound, and methods for treating or preventing, e.g., pain, depression and anxiety, in a patient comprising administering to a patient in need thereof an effective amount...

20060074091 - Nootropic effect enhancer: h

20060074092 - Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases: or a pharmaceutically acceptable salt or ester thereof (I), wherein the symbols have meaning as defined, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g., various disorders including inflammation, rheumatoid arthritis, osteoarthritis, osteoporosis and tumors....

20060074093 - Fungicidal mixtures: where X1 and X2 are halogen, nitro, cyano, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, haloalkoxy, haloalkylthio, alkylsulfinyl or alkylsulfonyl; x is 1, 2, 3 or 4; and y is 1, 2, 3, 4 or 5; in a synergistically effective amount, methods for controlling harmful fungi using mixtures of the...

20060074094 - Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia: The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the...

20060074095 - Novel purine derivatives, preparation method and use as medicines: e

20060074096 - 4-imidazolyl substituted pyrimidine derivatives with cdk inhibitory activity: Compounds of the formula (I): wherein R1, R2, R3, R4, R5 and p are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation)...

20060074097 - Regulation of mammalian keratinous tissue using hexamidine compositions: A method of facilitating the cosmetic delivery of a hexamidine compound to keratinous tissue via a composition including the hexamidine compound, including the step of incorporating a thickening agent that is not negatively-charged into the composition....

20060074099 - Crystalline forms and process for preparing spiro-hydantoin compounds: wherein Z is N or CR4b; K and L are independently O or S; Ar is an optionally substituted aryl or heteroaryl; A2 is a linker, G′ is a linker; Q is a linker; and R2, R4a, R4c, and Rh are defined in the specification. The process optionally includes the...

20060074098 - Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors: The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal deposition of A-beta protein....

20060074100 - Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases: Ophthalmic compositions containing HDAC inhibitors and their use for treating ocular neovascular or edematous diseases and disorders are disclosed....

20060074101 - Method of treating post operative nausea and vomiting: Methods are provided to teat post-operative nausea and vomiting, as well as emeses generally, with 5-HT3 receptor antagonists. In particular, the invention discloses methods for reducing post-operative nausea and vomiting and other emetic events with palonosetron....

20060074103 - Cyclic beta-amino acid derivatives as factor xa inhibitors: The present application describes cyclic β-amino acid derivatives or pharmaceutically acceptable salt forms thereof, wherein the central core is a non-aromatic carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa....

20060074102 - Kinase inhibitors as therapeutic agents: e

20060074104 - Use of clioquinol for the therapy of alzheimer's disease: The invention relates to the identification of clioquinol as a pharmaceutically therapeutic agent for treatment of Alzheimer's disease and related pathological conditions....

20060074105 - Substituted quinoline and quinazoline inhibitors of quinone reductase 2: The present invention provides composition and methods of inhibiting quinone reductase 2 (QR2). The methods are useful in the treatment of malaria and autoimmune diseases. The compositions of the invention comprise quinoline and quinazoline derivatives. The invention also provides methods for inhibiting the activity of QR2 by contacting the enzyme...

20060074106 - Treatment of inflammatory disorders: A method of treating an inflammatory disease or an autoimmune disease in a subject, comprises the administration of mefloquine....

20060074107 - Pharmaceutically active piperidine derivatives: m

20060074108 - Matrix metalloprotease (mmp) inhibitors and their application in cosmetic and pharmaceutical composition: This invention relates to compounds that are selective inhibitors of Matrix Metalloprotease (also known as Matrix Metalloproteinase, MMP), to cosmetic and pharmaceutical compositions containing them, and to their use in the prevention and/or treatment of ailments associated with MMP, including inflammation, wound healing, skin aging, skin tone discoloration, body odor,...

20060074109 - Use of inhibitors of 24-hydroxylase in the treatment of cancer: The present invention relates to a method of treating cancer in a subject. The method comprises administering to a subject suffering from cancer a therapeutically effective amount of a 24-hydroxylase inhibitor. In certain embodiments, the 24-hydroxylase inhibitor can be coadministered with calcitriol....

20060074110 - Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4: Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease,...

20060074111 - Chemical compounds: R6 is phenyl or a 6 membered heteroaryl group containing 1, 2 or 3 N atoms wherein the phenyl or heteroaryl group is optionally substituted with 1, 2 or 3 moieties selected from the group consisting of C1-6 alkyl, halogen, —OC1-6 alkyl, —SO2C1-3 alkyl, phenyl (optionally substituted by one or...

20060074112 - N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as vegf receptor tyrosine kinase inhibitors: Described are compunds of formula (I), wherein W is O or S; X is NR8; Y is CR9R10—(CH2)n wherein R9 and R10 are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO2; R1...

20060074113 - Thiadiazoline derivative: s

20060074114 - Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids: Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also...

20060074115 - Novel hexafluoroisopropanol substituted ether derivatives: s

20060074116 - 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation....

20060074117 - Purification of olmesartan medoxomil: The present invention provides a process for purifying olmesartan medoxomil....

20060074118 - 1, 2, 4 - triazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same: A 1,2,4-triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided....

20060074119 - Thiophene compounds: 1

20060074121 - Bicyclic and bridged nitrogen heterocycles: Compounds are provided that act as potent modulators of one or more of the CCR1, CCR2 and CCR3 receptors. The compounds are generally fused-, spiro- or bridged-nitrogen heterocycles having an aryl and heteroaryl component and are useful in pharmaceutical compositions, methods for the treatment of CCR1-, CCR2- and/or CCR3-mediated diseases,...

20060074122 - Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them: R5, R6 and R7 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, OR8, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1-6C)alkyl, (1-6C)alkoxy, aryl, aryl(1-6C)alkyl, heteroaryl, heteroaryl(1-6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl,...

20060074120 - Selective non-steroidal glucocorticoid receptor modulators: The present invention encompasses compounds of Formula (I) or pharmaceutically acceptable salts or hydrates thereof, which are useful as novel non-steroidal selective glucocorticoid receptor modulators for treating a variety of autoimmune and inflammatory diseases or conditions, and possess advantages over steroidal glucocorticoid ligands with respect to undesireable side-effects, efficacy, toxicity...

20060074123 - Cyclic amp-specific phosphodiesterase inhibitors: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed....

20060074124 - Methods of treating a disorder: v

20060074125 - Novel dithiolopyrrolones with therapeutic activity: The present invention provides novel dithiolopyrrolone compounds and their salts, which are useful as treatments for cancer and other proliferative diseases. The present invention also provides therapeutic compositions comprising particularly useful types of dithiolopyrrolones, the salts thereof, and methods of using the compounds within such types, particularly in treating proliferative...

20060074126 - Chroman derivatives, medicaments and use in therapy: Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described....

20060074127 - Substituted chroman derivatives, medicaments and use in therapy: Novel substituted chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described....

20060074128 - Substituted 2-phenyl benzofurans as estrogenic agents: v

20060074129 - Method for obtaining ozonized oils and vegetable fats and use of said products for pharmaceutical and cosmetic purposes: This invention is linked to the chemical, pharmaceutical and cosmetic industries, where the bactericidal, virucidal, parasiticidal and fungicidal properties of the ozonized vegetable oils and fats are considered. The emulsified vegetable oil or fat is driven to react with ozone in a bubbling reactor, covered by a jacket that makes...

20060074130 - Methods of using substituted tetralins and indanes: The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, diabetes....

20060074131 - Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof: This invention relates to a highly thermally stable novel anhydrous crystalline polymorphic form of venlafaxine hydrochloride, methods for the preparation thereof, and its use....